Cardiovascular Redox and Ox Stress Proteomics

Vikas Kumar,^{1,*} Timothy Dean Calamaras,^{2,*} Dagmar Haeussler,¹ Wilson Steven Colucci,²
Richard Alan Cohen,¹ Mark Errol McComb,³ David Pimentel,^{2,*} and Markus Michael Bachschmid^{1,3,*}

Abstract

Significance: Oxidative post-translational modifications (OPTMs) have been demonstrated as contributing to cardiovascular physiology and pathophysiology. These modifications have been identified using antibodies as well as advanced proteomic methods, and the functional importance of each is beginning to be understood using transgenic and gene deletion animal models. Given that OPTMs are involved in cardiovascular pathology, the use of these modifications as biomarkers and predictors of disease has significant therapeutic potential. Adequate understanding of the chemistry of the OPTMs is necessary to determine what may occur *in vivo* and which modifications would best serve as biomarkers. **Recent Advances:** By using mass spectrometry, advanced labeling techniques, and antibody identification, OPTMs have become accessible to a larger proportion of the scientific community. Advancements in instrumentation, database search algorithms, and processing speed have allowed MS to fully expand on the proteome of OPTMs. In addition, the role of enzymatically reversible OPTMs has been further clarified in preclinical models. **Critical Issues:** The identification of OPTMs suffers from limitations in analytic detection based on the methodology, instrumentation, sample complexity, and bioinformatics. Currently, each type of OPTM requires a specific strategy for identification, and generalized approaches result in an incomplete assessment. **Future Directions:** Novel types of highly sensitive MS instrumentation that allow for improved separation and detection of modified proteins and peptides have been crucial in the discovery of OPTMs and biomarkers. To further advance the identification of relevant OPTMs in advanced search algorithms, standardized methods for sample processing and depository of MS data will be required. *Antioxid. Redox Signal.* 17, 1528–1559.

Introduction

FOR MORE THAN a century, the role of *in vitro* and *in vivo* amino-acid oxidation has been studied (58); however, the extent to which these post-translational modifications occur and their effects on cellular biology still remain uncertain. Direct evidence for oxidative post-translational modifications (OPTMs) of amino acids, occurring *in vitro*, was shown more than 50 years ago by demonstrating that reactive nitrogen and oxygen species (RNOS) could directly cleave peptide bonds and modify amino-acid side chains (264, 275). In cells, the capacity for OPTMs to alter protein function can be accounted for by reversible or irreversible modifications. Reversible OPTMs can modulate physiological protein function and are enzymatically reducible and, therefore, reversible. The sulfur-containing amino acids, methionine (Met), and cysteine (Cys)

are the only oxidized amino acids that are enzymatically reduced and are, therefore, the most likely candidates which regulate physiological redox signaling events. Alternatively, irreversible OPTMs are persistent, typically occur through nonenzymatic processes, can lead to protein inactivation and structural changes, and ultimately require protein degradation and resynthesis for reversal. These include the hydroxylation of aromatic groups and aliphatic amino-acid side chains, nitration of aromatic amino-acid residues, oxidized lipid adduction, conversion of amino-acid residues to carbonyl derivatives, and higher oxidation states of thiol groups. Although these are often associated with progressive protein and cellular dysfunction, irreversible modifications have been observed during normal physiologic responses as well. For example, the hypoxia-inducible factor 1, alpha subunit (HIF1 α) is constitutively hydroxylated on specific proline

¹Vascular Biology Section, ²Myocardial Biology Unit, and ³Cardiovascular Proteomics Center, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.

*These authors have equally contributed to this work.

residues by HIF prolyl-hydroxylase, marking the protein for ubiquitination and rapid degradation by the proteasome pathway under conditions of normoxia (152). The ability to investigate oxidatively modified proteins and to identify specific OPTMs has been improved through the recent development of novel tools and technologies that monitor redox modifications, including mass spectrometry and advanced peptide labeling techniques. In the cardiovascular system, cardiac and skeletal myofibrillar proteins from patients with heart failure, including troponin I (41), are oxidatively modified and may serve as potential biomarkers of the cardiovascular dysfunction. For the finer detection of cardiovascular OPTM-sensitive signaling cascades and proteins, or *redox proteomes*, mass spectrometry has been proposed as an improvement for identification. However, due to the variety, stability, and complexity of OPTMs, the analytic evaluation of the *redox proteome* differs (Fig. 1). The aim of this review is to address the formation of various redox proteomes in the cardiovascular system and demonstrate the relationship of these to animal pathology and biomarker identification.

Redox Signaling Versus Oxidative Stress

Compared with typical cellular signals, RNOS were initially thought to be too unstable and short lived to have relevant biological effects or to function as signaling molecules. However, with the discovery of the antioxidant enzyme superoxide dismutase (SOD) by Fridovich and McCord (182, 183), the physiological relevance of RNOS was established. At the beginning of this new research era, it was believed that the oxidation of biological molecules was a side reaction derived from the necessity of utilizing oxygen to generate cellular energy in the form of adenosine-5'-triphosphate (ATP). During the generation of cellular ATP, ~0.1% of oxygen consumed by mitochondria is converted into RNOS. This phenomenon is due to the misdirection of electrons from the respiratory chain to molecular oxygen, resulting in the one-electron reduction product superoxide ($\text{O}_2^{\cdot-}$). In the presence of transition metals ions such as iron (Fe), copper (Cu), organic radicals, or enzymes such as peroxidases, $\text{O}_2^{\cdot-}$ can be quickly converted into more reactive RNOS, which readily oxidizes biological molecules. This group of RNOS includes the hydroxyl radical ($\text{OH}^{\cdot}$), carboxyl radical ($\text{CO}_2^{\cdot-}$), nitric oxide ($\text{NO}^{\cdot}$), and ($\text{NO}_2^{\cdot}$) as well as the nonradical species hydrogen peroxide (H_2O_2), hypochlorous acid (HOCl), singlet oxygen ($^1\text{O}_2$), carbon monoxide (CO), and nitrogen dioxide (NO_2) (94, 128, 265, 292).

In contrast to the assumption that RNOS were solely derived from oxidative metabolism, the immunology field recognized the antiseptic properties of RNOS for cellular host defense. Neutrophil granulocytes generate large amounts of superoxide through nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (containing the cytochrome binding subunit called gp91^{phox} or NADPH oxidase [NOX]-2). The spontaneous decomposition of $\text{O}_2^{\cdot-}$ or catalysis by SODs results in H_2O_2 formation. Myeloperoxidase further converts this reactive oxygen species (ROS) into HOCl, a highly bactericidal agent that is believed to kill phagocytosed pathogens and activate the proteases required for phagocytosis (109). This process was termed "oxidative burst" and in macrophages, an alternate second system consisting of inducible NO-synthase (iNOS or NOS-2) was found to produce

FIG. 1. Interaction of proteome with reactive nitrogen oxygen species (RNOS). In addition to traditional post-translational protein modifications (phosphorylation, acetylation, ubiquitination, *etc.*), cellular proteins can be modified by RNOS, adding another layer of protein regulation to the proteome classified as oxidative post-translational modifications (OPTMs). OPTMs are reversible or irreversible—reversible oxidation is generally involved in the regulation of cell signaling or the protection of proteins from irreversible oxidation, whereas irreversible oxidation is mostly associated with pathophysiology and protein degradation. Both reversible and irreversible modified proteins may be potential biomarkers of oxidant-mediated pathologies.

reactive nitrogen species. Discovery of the oxidative burst demonstrated that cellular RNOS formation was controlled, and the resulting OPTMs were identified as markers of inflammation. Various irreversible OPTMs were discovered and utilized as molecular footprints of RNOS generation, including protein-bound nitrotyrosine, protein carbonyls, lipofuscin (35, 180, 258), malondialdehyde (MDA) (93), ceroid bodies (101), and dityrosine crosslinks. These markers led researchers to hypothesize that cardiovascular diseases (CVDs) such as ischemia reperfusion injury and atherosclerosis, ionizing radiation-induced damage, and xenobiotic metabolism may involve the damaging effects of RNOS on biological molecules contributing to the pathophysiological process (94, 301).

Discovery of the various isoforms of NO synthase and NOX in the cardiovascular system led to the widespread recognition of RNOS as important signaling molecules (other cellular sources of radicals are listed in Table 1). Physiologically, RNOS levels range in the submicromolar concentration (12, 137, 178, 220, 224, 262) and can directly react with various amino-acid residues to alter protein activity and function (112, 120). RNOS can also affect carbohydrates (98, 189) and lipids to generate oxidative by-products that react with proteins and modify cellular signaling (71). In order to produce distinct signaling events, sufficient quantities of RNOS should act locally and modify a protein reversibly or irreversibly, resulting in a defined functional change. These RNOS-controlled signaling events can be subcategorized into *oxidative signaling* (Fig. 1), which includes irreversible OPTMs that lead to specific signaling events. The activation of cellular antioxidant defenses as modulated by the Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 complex is a prime

example. Various genes that are important for type II detoxification of RNOS and electrophiles are under control of the antioxidant- or electrophile-response element (ARE), including SODs and enzymes involved in glutathione metabolism. Reactive electrophiles, such as 4-hydroxynonenal (HNE), or RNOS can react irreversibly with critical Cys residues on Keap1, leading to its dissociation from Nrf2 and to ubiquitin-mediated degradation of Keap1 (151). Free Nrf2 then translocates to the nucleus, heterodimerizes with the Maf protein, and interacts with the AREs to promote the transcription of genes involved in oxidant detoxification.

The second category of RNOS-controlled signaling is *redox signaling* (Fig. 1), which should be, by definition, enzymatically reversible. S-glutathionylation and S-nitrosylation (nitrosation) of HRas are excellent examples of this type of signaling. HRas is a key regulator of the propagation and amplification of receptor tyrosine (Tyr) kinase-mediated growth signals *via* the mitogen activated protein (MAP) kinase pathway (114). HRas tethered to the plasma membrane are reversibly modified at a critical Cys residue by the RNOS derived from NOX and NO synthases, and this modification leads to enhanced guanosine diphosphate dissociation and activation (53). Enzymatic systems such as glutaredoxin (Grx) can then remove the S-glutathione adduct from the HRas to cease signaling (3, 165). The example of HRas is a further illustration by which RNOS may increase locally and target specific microdomains in the cell. In order to properly signal, HRas should be shuttled from the Golgi apparatus to the plasma membrane, and on termination of the signaling, the HRas are transported back to the Golgi. One may speculate that oxidases localized at the plasma membrane oxidatively modify and activate HRas and that translocation back to the Golgi may require reversal of the oxidative modification in HRas by the cellular reducing enzymes, thus terminating the signal. A recent publication from our group demonstrates that the shuttling of HRas, which is controlled by the palmitoylation of C-terminal Cys residues, is redox controlled as well (36).

From these examples, it is evident that the transition from redox to oxidative signaling in a cellular environment may not be easily distinguishable. Furthermore, higher and uncontrolled RNOS levels, or *oxidative stress* (Fig. 1), leading to multiple sites of irreversible OPTMs in many proteins may interfere with signaling cascades.

Regardless of this, the inhibition of the formation of these irreversible OPTMs may be therapeutic in delaying the aging process and associated pathologies (194). In terms of functional consequences, one can speculate that oxidative signaling, redox signaling, and oxidative stress allow for distinct proteomes to be affected, each of which warrants a separate analytical investigation.

Types of OPTM—Consideration of Reactivity, Topology, and Biological Effects

RNOS-induced protein changes can be classified as modifications that lead to cleavage of the peptide backbone (Fig. 2) or those that modify amino-acid side chains (27, 60, 78, 90, 263, 264). The former group includes the direct attack by a hydroxyl radical on glutamate residues, which converts the amino acid into pyruvic acid and ammonia or a reaction of the hydroxyl radical with a proline residue, forming aminobu-

tyric acid and carbon dioxide (CO₂). Also included in this category are the initial amino-acid side-chain modifications such as aldehyde production, which transfers the radical to the protein backbone *via* alkoxy radicals (62, 77, 118, 119, 199, 202, 221, 312). Meanwhile, the latter includes direct oxidation of the amino-acid side chains as well as lipid and sugar oxidation by-products that form adducts with the side chains. All these oxidatively derived PTMs produce altered proteins that can be termed the *redox proteome* or *redoxome* (141). These modifications are most often described as functional changes, but, alternatively, some may act as antioxidant shields that prevent deleterious protein oxidation (162, 173, 231).

The *proteome* of OPTMs can be further subdivided into two groups as described in Figure 1. The reversible group, which will be referred to as the *redox proteome*, includes oxidative post-translationally modified proteins that mediate signaling events under normal physiological conditions and likely belong to the enzymatically reducible thiols of Met and Cys residues. The irreversible group would encompass OPTMs that occur under conditions of oxidative signaling or oxidative stress (Ox Stress proteome).

The oxidative modification of protein-bound amino acids depends on various biological and chemical aspects of the target amino-acid residues, including topology, steric accessibility, chemical reactivity, physiochemical properties, and subcellular localization of the protein (Table 2). RNOS preferentially react with amino acids that are in solvent or surface exposed and are less likely to reach residues that are buried inside the protein structure. Furthermore, proteins that exist in their constitutive form as a dimer or multimer will be less prone to modifications at the contact site of the interacting proteins.

Nevertheless, OPTMs can be found on inaccessible residues, which suggests that the OPTMs may partially alter and unfold the protein to expose concealed residues, may target residues during protein synthesis and folding that are otherwise less accessible, or may transfer and tunnel radicals and electrons, respectively, from the amino-acid side chain to the protein backbone. This effect might be of particular interest for plasma proteomics, as a protein such as serum albumin could already be cotranslationally modified in the liver, revealing a local organ specific pathology; whereas the correctly folded circulating protein may be modified at another site as a "passerby" in the circulation. Thus, protein turnover may indirectly provide a footprint for the formation of RNOS and OPTMs at distinct cellular compartments.

A second aspect of factors that affect OPTM formation is that proteins may localize to different subcellular compartments that have a distinct redox state. For example, OPTMs of manganese SOD in the mitochondria would indicate mitochondrial dysfunction, which has been detected in various diseases (175) and the aging process (290, 291, 304). Depending on whether a protein is a transmembrane, membrane associated, or cytosolic protein, the subcellular location of the exposed amino acid can affect the protein residues that are targeted for modification by RNOS. RNOS-mediated lipid peroxidation products, including electrophilic aldehydes, would most likely target proteins that are in proximity to the site of peroxide formation, specifically at cellular membranes. Conversely, charged RNOS species are unlikely to affect amino-acid residues that are surrounded by membrane lipids. In addition, as demonstrated by Radi

TABLE 1. REACTIVE NITROGEN AND OXYGEN SPECIES SOURCES

Source	Description	Capacity
Mitochondria	<p>Source of superoxide Complex I ubiquinone binding site Complex III ubiquinone binding site—Accumulation of ubisemiquinone To date it is unclear whether mitochondrial $\bullet\text{O}_2^-$ generation is accidental or can be regulated by, for example, mitochondrial anion channel, uncoupling proteins (UCP), oxidative modifications of complex I, or inhibition of complex IV <i>via</i> $\bullet\text{NO}$.</p> <p>Source of nitric oxide Putative mitochondrial NO synthases (NOS-3 (heart) or an NOS-1 splice variant) Reduction of nitrite at Complex III—under hypoxia</p>	<p>High up to 0.1% of utilized O_2</p> <p>Low, depending on oxygen tension</p>
Nitric oxide synthase	<p>Source of nitric oxide NOS I/Nnos Neuronal NO-Synthase 160 kDa Regulation <i>via</i> Ca^{2+}/calmodulin Splice variants—mitochondrial NO synthase Mainly nervous system and splice variants in skeletal and vascular smooth muscle (nNOSu) N-terminal PDZ domain that is important for interaction with syntrophin. Attachment of nNOS to membranes (plasma, sarcolemma, and endoplasmic reticulum) <i>via</i> dystroglycan-dystrophin and dystrobrevin complexes or in neurons association with NMDA receptor <i>via</i> PSD-95, Capon, and Dexas Caveolin III, phosphofructokinase M NOS II/iNOS iNOS 125–135 kDa Ca^{2+}/calmodulin is tightly bound to the enzyme and leads to constitutive activation Cytosolic Induced as early immediate genes on inflammatory stimuli such as LPS or cytokines NOS III/eNOS Endothelial NO-synthase 135 kDa Vascular endothelium Regulation <i>via</i> Ca^{2+}/calmodulin (10–20-fold change in activity) Caveolin I association inhibits the enzyme—“Caveolar Paradox” Phosphorylation at Ser 1177 (positive regulator at the reductase domain) and Thr495 (negative regulator at the Ca^{2+}/calmodulin binding domain) can cause activity changes of approximately 2–3-fold. Function: Vascular adaptation to shear stress or reaction to stimuli such as estrogen, insulin, bradykinin, or VEGF Phosphorylation by Akt/PKB and PKA, and PKC Palmitoylation and myristoylation target the enzyme to the plasma membrane Associates with HSP90, bradykinin receptor, and CAT-2</p> <p>Source of superoxide—uncoupled NO synthase Uncoupling occurs under reduced availability of either L-Arg or tetrahydrobiopterine (BH_4) Low-temperature SDS-PAGE monomer and dimer distribution as an indicator of the status of the Zn-finger, involved in uncoupling Phosphorylation of Ser-1177 Heat shock protein 90 (HSP90) and its inhibitor geldanamycin. Recent data indicate that HSP90 can improve NO release but does not contribute to eNOS uncoupling</p>	<p>Low-medium Nmolar fluxes</p>
NOX (NOX = homologues of gp91 ^{phox})	<p>Source of superoxide: NOX 1=NOX 1 participates in the regulation of cell proliferation <i>via</i> activation of MAP kinase cascade. Separate cytosolic components Important isoforms in the vasculature</p>	<p>Low in the vascular system, but high in neutrophils (oxidative burst)</p>

(continued)

TABLE 1. (CONTINUED)

Source	Description	Capacity
	NOX 2=gp91 ^{phox} , homologous to the phagocyte oxidase but with lower $\bullet\text{O}_2^-$ and intracellular output. Forms an active complex with membrane (gp22 ^{phox}) and cytosolic (p40 ^{phox} , p47 ^{phox} , p67 ^{phox} , and Rac 1,2) components	
	Source of H_2O_2	
	NOX 4	
	Induction and activation <i>via</i> Angiotensin II	
	Inhibition of activation <i>via</i> inhibitors that interfere with the complex formation such as apocynin, gliotoxin, or phenylarsene oxide (PAO)	
	Positive $\bullet\text{O}_2^-$ feedback <i>via</i> PKC.	
Xanthine oxidase	Source of superoxide and H_2O_2 Conversion of the xanthine dehydrogenase into an oxidase by Reversible and irreversible oxidation of essential sulfhydryls Proteolysis Extracellular xanthine oxidase is synthesized in the liver and sticks <i>via</i> proteoglycans to the endothelial surface.	Medium, depending on its substrate availability
	Source of nitric oxide: Reduction of nitrite to $\bullet\text{NO}$ under hypoxic conditions - putative autoregulatory mechanism	Low, depending on oxygen tension
Hemoglobin/ myoglobin	Source of nitric oxide: Reduction of nitrite to $\bullet\text{NO}$ under hypoxic conditions - putative autoregulatory mechanism for capillaries and muscle	Low, depending on oxygen tension

Arg, arginine; eNOS, endothelial nitric oxide synthase OR NOSIII; H_2O_2 , hydrogen peroxide; iNOS, inducible NO-synthase; MAP, mitogen activated protein; NOX, NADPH oxidase; PKA, cAMP dependent protein kinase; SDS PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; VEGF, vascular endothelial growth factor.

et al. (223), the membrane and its interface may promote a different chemistry for RNOS reactions, as certain species, including nitric oxide and various peroxides, are lipid soluble. These observations apply all the more to different cell types and tissues in which OPTMs in cell- or tissue-specific proteins are being investigated as meaningful and specific biomarkers.

A third aspect is the physiochemical properties and microenvironment of protein amino-acid residues, which may largely affect their reactivity. Cys residues, as explained in greater detail in a later section, are highly reactive as a thiolate and, in some proteins, can exert a peroxidase-like function. OxyR, a H_2O_2 sensing protein in *E. coli*, possesses a reactive thiolate within a lipophilic pocket. The geometry of the pocket, its lipophilicity, and the reactivity of the Cys determines its specificity for H_2O_2 as a substrate compared with other RNOS. Such structural arrangements of the protein are not only advantageous for cellular redox signaling but also make these residues prone to oxidative stress.

Lastly, the redox state of the cell plays a crucial role in the formation of OPTMs on proteins. For instance, the cellular redox state can dramatically change during the cell cycle, allowing for cell division, DNA synthesis, metabolic adaptation, and DNA dissemination to the daughter cell. During mitosis, the nuclear envelope dissolves, and the nuclear segregated content is adjusted to the cytoplasmic redox conditions. Moreover, the differential activation of cellular $\bullet\text{NO}$ and superoxide sources may change the type of reactive species formed. The cell can transition from primary $\bullet\text{NO}$ signaling, which is, for example, used by the vascular endothelium to control the vascular tone

under homeostasis, to a more oxidative state during endothelial inflammation, which promotes the formation of more reactive RNOS through the activation of superoxide sources. In addition, leukocyte recruitment during the inflammatory process results in the concomitant release of high levels of superoxide and nitric oxide, leading to the formation of the very reactive peroxyxynitrous acid. This species nitrates Tyr residues, and in the case of the endothelium, inhibits the formation of the important homeostatic mediator prostacyclin.

Depending on these various aspects, signaling or pathologic events can be induced by OPTMs, with each separate protein amino acid serving as a sub-proteome for oxidative modifications. In addition, the irreversible oxidation of proteins can hypothetically occur before cellular dysfunction, and, thus, these OPTMs can be used as early biomarkers of disease. We will discuss the chemistry of each oxidatively altered protein amino acid and the corresponding sub-proteome, the tools used to measure these and the *in vivo* significance of the specific Redox and Ox stress proteomes as they pertain to the cardiovascular system.

Cysteine

When considered from an evolutionary point of view, Cys is one of the most conserved amino-acid residues within protein sequences from species to species, which highlights its importance in overall protein structure and function (80). Cys modifications can lead to changes in catalytic activity by altering enzyme protein stability through changes in the protein structure. Redox reactivity of Cys is governed by the thiol

FIG. 2. Oxidative cleavage of proteins—peptide bond cleavage.

(R-SH) group on its side chain (Fig. 3). Generally, Cys involved in redox reactions are located in the vicinity of arginine (Arg), lysine (Lys), or histidine (His) residues, resulting in a lower pKa, which is the pH at which 50% of the thiol is deprotonated and, thus, more reactive. Adjacent hydroxyl groups from serine or Tyr can also stabilize the thiolate by hydrogen bonding. The thiolate anion (R-S⁻) is the most reactive cellular nucleophile, and it can change enzyme activity, substrate recognition, and allosteric regulation.

Cys modifications have been identified by the use of antibodies and labeling techniques. The thiol-containing side chain reacts with numerous chemical reagents and allows for the labeling of oxidized Cys in a sample. This is generally done by alkylating with a thiosulfonate, reducing the sample to remove the reversible modification and then re-alkylating with a tagged thiosulfonate. These may then be used for immunoblotting, immunohistochemistry, or mass spectrometry. As a word of caution, one thiosulfonate, maleimide, at higher concentrations can undergo nonspecific side reactions with Lys or His, complicating the analysis of specifically tagged Cys (this is unlikely to occur while using nanomolar or low micromolar concentrations of the alkylating agent). A direct measure of peptide mass changes in a Cys can be used for OPTM detection by MS, and these include *S*-glutathionylation (+305 Da), *S*-

sulfonylation (+80 Da), *S*-cysteinylation (+119 Da), di-sulfide (−2 Da), sulfinic acid (+32 Da), and sulfonic acid (+48 Da) (115).

Most detection methods, including MS, incorporate the use of labeling techniques that selectively enrich the fraction of oxidized Cys residues. Using an iodoacetamide-based fluorescent probe that labels reversibly oxidized Cys (19), 50 reactive thiol-containing proteins were identified, separated by two-dimensional gel electrophoresis (2DE), and the extent of oxidation was evaluated with the light emitted from fluorescently probed proteins. Using a similar approach with indocarbocyanine, Cy3 and indocarbocyanine, and Cy5 labeled maleimide, each of which have a distinct excitation and emission wavelength, differentially oxidized free thiols were labeled, compared by differences in emission, and extracted from the gel for MS/MS detection (86). Quantitative MS approaches can utilize thiol-reactive isotopic or isobaric tag based, including isotope-coded affinity tags (ICAT), as shown in Figure 4 (105) and can eliminate the short comings of gel extraction methods (61). ICAT is available in two forms, heavy or light, depending on the carbon isotope present in the thiol-reactive iodoacetamide. With ICAT, one sample can be labeled with heavy ICAT and the other, with light ICAT, introducing a 9 Da difference between the Cys-labeled peptides. The mass

TABLE 2. FACTORS AFFECTING OXIDATIVE POST-TRANSLATIONAL MODIFICATIONS

Topology	<p>Surface- and solvent-exposed amino-acid residues are the preferred reaction partners for RNOS compared with intramolecular residues.</p> <p>Maturation and folding state of the protein will determine the exposure of amino-acid residues.</p> <p>Oxidative and other PTMs may alter the protein structure by partially unfolding the protein, splitting it into smaller subunits, or forming disulfide bonds.</p> <p>The protein interface/domain for dimer or multimerization will prevent the access of RNOS to underlying amino-acid residues.</p>
Cellular compartments	<p>Subcellular localization of the protein (plasma membrane, mitochondria, lyso-, peroxi-, endo- or exosomes and others, sarco- or endoplasmic reticulum, Golgi apparatus, and nucleus).</p> <p>Transmembrane, membrane-associated, or cytosolic proteins.</p> <p>Intracellular, surface or secreted proteins.</p> <p>Organ- or cell-type-specific proteins.</p> <p>May want to mention differences in the reactivity of cellular components (mito <i>vs.</i> nuc)</p>
Physicochemical properties	<p>Lipophilic and hydrophilic sections or pockets on the protein.</p> <p>Repulsion or attraction by surface charges.</p> <p>Charge state of certain amino acids, including Cys, Lys, and Arg ($-SH$ <i>versus</i> $-S^-$; $-NH_2$ <i>versus</i> $-NH_3^+$) determines their reactivity.</p> <p>Vicinal protein side chains can alter the reactivity of the surrounding amino acids.</p>
Cellular antioxidant status–radical fluxes	<p>Ratio of radical fluxes of nitric oxide ($\bullet NO$) and superoxide ($\bullet O_2^-$) will determine the formation of specific RNOS.</p> <p>The redox state of the cell determines the amount and fluxes of RNOS.</p> <p>Experimental conditions: Fluxes <i>versus</i> bolus addition may lead to different OPTMs.</p> <p>Experimental conditions: Efficacy of genetically expressed antioxidant enzymes can be modulated through localization sequences that target antioxidants to specific cellular components.</p>
Chemistry of the OPTM	<p>Release or overload with redox-active transition metals, including Fe and Cu.</p> <p>Direct reaction of RNOS with amino-acid residues <i>versus</i> reaction with reactive compounds derived from RNOS-mediated degradation of lipids and carbohydrates.</p> <p>Transition metal-catalyzed reactions.</p>

Cu, copper; Cys, cysteine; Fe, iron; OPTM, oxidative post-translational modification; RNOS, reactive nitrogen and oxygen species

difference is then detected by MS, and the relative quantities of the two peptides can be obtained. Using this technique, oxidized creatinine kinase was identified by Sethuraman *et al.* by liquid chromatography tandem mass spectrometry (LC-MS/MS) (249) and since then, has been utilized to identify modified myocardial proteins after exposure to H_2O_2 as well as myocardial proteins sensitive to thioredoxin (Trx) and nuclear proteins in mice (86, 97, 250). The advantage of using ICAT is that it allows for the simultaneous identification and quantification of redox-sensitive Cys residues (157). ICAT is also advantageous for (i) screening hydrophobic proteins, for example, sarcoplasmic/endoplasmic reticulum Ca^{2+} ATPase (SERCA) (86), which are poorly resolved by 2DE; (ii) evaluating proteins with high pI values exceeding the limits of 2DE, for example, cytochrome c oxidase (pI 8.96); and (iii) identifying numerous peptide ratios from a single sample. ICAT is limited by its poor peptide sensitivity either due to retention on the reverse-phase LC or poor ionization and/or fragmentation of certain peptides in the mass spectrometer. The interpretation of results using ICAT can be confounded by inadequate peptide identification due to the low intensity of one of the ICAT pairs or by improperly accounting for expression changes that could be misinterpreted as oxidation. Changes in expression, though, could be corrected by using another method in parallel, such as isobaric tag for relative and absolute quantitation (iTRAQ) (87). Further refinement of the methodology may allow for ICAT to be the approach of choice when determining oxidative changes

in vivo under physiological oxidative stress. ICAT, however, does not allow a comparison of more than two samples in parallel. To perform multiple comparisons, thiol-specific cysteine specific tandem mass tags (CysTMT), which are pyridylthiol-based reversible tags with similar masses (isobaric) that result in the generation of a reporter ion with different masses, and that can vary by 1 Da and be detected by tandem MS, could be utilized (198).

Novel mapping of reactive Cys have been proposed using an IsoTOP-ABPP (isotopic tandem orthogonal proteolysis activity-based protein profiling) that uses an iodoacetamide reactive probe coupled to an azide functionalized TEV protease recognition site containing a biotin tag. The tag contains a site that can then accommodate either a light (standard) or (heavy) labeled valine which can allow the differential labeling and quantification of peptides (296, 297) by MS. In addition to this, computational or *in silico* methods have been developed to determine the most likely redox-active Cys residues present (82).

S-Nitrosylation. The thiolate anion can undergo a direct oxidative modification through the action of nitric oxide to form an S-nitrosylation modification. S-nitrosylation can occur chemically on thiols *via* NO-derived species such as N_2O_3 (NO^+), transfer or transnitrosation reactions, or by interaction with metalloprotein-linked enzymes (248). The principle method used to detect S-nitrosylation is the biotin

FIG. 3. Enhanced cysteine (Cys) reactivity in the presence of catalytic diad/triad.

switch assay in which free thiols are initially blocked with an alkylating agent or reactive thiolsulfonate, such as MMTS; the *S*-nitrosylated thiols are reduced with ascorbate; and then, the free Cys thiols are labeled with a biotinylated alkylating agent, such as biotin *N*-(6-[biotinamido]hexyl)-3'-(2'-pyridyldithio) propionamide for subsequent pull-down and immunoblotting (131). This assay is fairly specific but should be performed in the absence of UV light, in the presence of metal chelators, and with fresh materials (83). Fluorescent labels have also been utilized to improve the detection of SNO peptides (146). Antibodies that detect *S*-nitrosylation also exist; however, these antibodies suffer from nonspecific binding to unmodified Cys residues (52). Since the SNO adduct is too labile to remain intact during purification schemes with reliability, the proteomic identification of *S*-nitrosylated proteins involves variations of the biotin switch assay in combination with mass spectrometry (131). Either this or novel labeling techniques using resin-assisted capture (RAC) or labeled tags in protein SNO can be used to evaluate RSNO by mass spectrometry (38, 51, 84). SNO-SID (SNO-site identification) was described to

identify SNO peptides, rather than proteins, by introducing a proteolytic step before protein pull-down (116). Forrester *et al.* have developed an assay combining the labeling and pull-down steps with a thiol reactive resin, thus creating an RAC for *S*-nitrosylation (SNO-RAC) (84). The use of SNO-RAC, which forms a covalent disulfide between the SNO and the resin, allows for trypsinization and peptide labeling directly on the resin that is rapidly followed by LC-MS/MS identification methods. SNO-RAC appears to be more sensitive than the biotin switch assay for high mass proteins and at least comparably sensitive for proteins smaller than 100 kDa.

Lastly, two methods have been developed to detect the endogenous *S*-nitrosothiol proteome. One method utilizes an organomercury resin that reacts with *S*-nitroso protein adducts to form a stable thiol-mercury bond, and then, the modified proteins can be identified with MS/MS (66).

The second method ESNOQ (endogenous SNO quantification) combines stable-isotope labeling of amino acids in cell culture (SILAC) with detergent free lysis followed by the

FIG. 4. Overview comparison of isotope-coded affinity tags (ICAT) strategies for oxICAT with standard ICAT. The first section in the figure shows components of the ICAT reagent consisting of a biotin-based affinity tag for purification, a linker group that can be cleaved by an acid after labeling, an isotopic tag which varies because it has heavy nine ^{13}C atoms instead of light ^{12}C atoms, and an iodoacetamide-based group which binds the reduced Cys in proteins. The second section shows a general strategy used for ICAT; all reversible thiols are reduced and labeled with ICAT. The third section shows the OxICAT (a modified ICAT method) that is used to study oxidized thiols; free thiols are blocked with a blocking reagent such as iodoacetamide, and, reversibly, oxidized thiols are labeled with ICAT. The fourth section depicts an overview of the ICAT strategy; samples are first labeled with heavy or light isotope reagent individually, then mixed, and, finally, subjected to tryptic digestion after affinity purification. Finally, both quantification and identification are achieved by mass spectrometry from MS and MS/MS data, respectively.

biotin switch assay and protein identification by LC-MS/MS (313). The latter two methodologies have the advantage of direct measurement of SNO-modified sites, as the other methods measure putative reaction sites (313).

The reversal of *S*-nitrosylation is accomplished by Trx (which also reduces intramolecular dithiols) in the cytosol or mitochondria (24, 25). In addition to the Trx system, *S*-NO adducts can form *S*-nitrosoglutathione (GSNO), which itself may undergo transnitrosation reactions with reactive thiols, or be reduced by GSNO reductase or alcohol dehydrogenase class III (168, 169). By using Trx reductase ablated mice, an association between *S*-nitrosylation and poor vascular relaxation was observed (50). This finding has been further buttressed by the GSNO reductase-deficient mouse that has diminished peripheral vascular tone and depressed β -adrenergic inotropic responses due to the denitrosylation of

cardiac ryanodine receptor 2 (RyR₂) (21). In addition, the deletion of GSNO reductase also increases tissue damage (222) and mortality after endotoxic exposure with more hypotension after anesthetic challenge, suggesting impaired responses of the vasculature (169). These mice also have attenuated myocardial infarct size due to increased angiogenesis that may be driven by HIF1 α *S*-nitrosylation-induced vascular endothelial growth factor (VEGF) expression (166). Similarly, the overexpression of Trx, which can reduce RSNO, attenuates infarct size by the same mechanism, further suggesting that infarct-related dysfunction may be modulated by *S*-nitrosylation (5). Novel tools such as mitoSNO may allow for the directed modulation of the *S*-nitrosylation of proteins in specific compartments (51) and better identification, localization, and role of specific SNO proteins.

FIG. 5. OPTMs by α, β unsaturated aldehydes. The family of α, β unsaturated aldehydes possess electrophilic and aldehyde groups that allow for two types of reactions: (i) Schiff base formation occurs with primary amine groups, primarily on lysine (Lys) residues but can modify arginine as well. (ii) Michael addition primarily occurs through interactions of the electrophilic group with the sulfhydryl group of Cys. Michael addition can also modify the imidazole group of histidine residues, the ϵ -amino group of Lys, and, to a lesser extent, the arginine side chains. The electrophilic and aldehydic moieties of this species allow for dual reactions to occur, thereby forming inter- and intramolecular crosslinks between protein chains under favorable conditions.

Sulfenylation. The thiolate can also undergo thiol shuffling reactions (203) or react with H_2O_2 to form a sulfenic (R-SOH) acid, also referred to as sulfenylation. Sulfenylation has been detected in the structural and mitochondrial proteins of cardiac myocytes treated with H_2O_2 (46, 241) and may be enzymatically reversed by Trx (277). At present, it is uncertain whether sulfenic acid can act as a signaling molecule, and speculation is that it acts as an intermediary for further oxidation only.

Sulfenylation can be analyzed and trapped by using the specific alkylating agent, 5,5-dimethyl-1,3-cyclohexanedione (dimedone) (9, 26, 46, 218). Typically, proteins forming a putative sulfenic acid are incubated with dimedone, and the protein containing the dimedone-modified Cys is then isolated and identified by tandem mass spectrometry, tagged purification, or antibody identification. The recent advent of newer dimedone analogs, based on the removal of two methyls from the ring of dimedone, DAZ, which is 1,3-cyclohexadione coupled to azide, and the 3-(2,4-dioxocyclohexyl)propyl (DCP) analogs, which couple Cys reactive DCP fluorophore groups to 1,3 cyclohexadione, have been synthesized as well (9, 283). The labeling of sulfenylation using these compounds should be performed as described by Poole and colleagues (149). The major limitation of dimedone is its poor cell permeability; thus, high concentrations of sulfenic acid are needed or elevated concentrations of dimedone or analogue are required (149), and in complex mixtures, it

competes with endogenous-free small-molecule thiols such as Cys, homocysteine, and glutathione, which react much faster with protein Cys-SOH (228). Other reagents used in the detection of sulfenic acid include 2-nitro-5-thiobenzoic acid (TNB), which may be a better agent for the identification of protein Cys-SOH, as it reacts faster than endogenous thiols or dimedone. For example, it can react with albumin Cys-OH at a rate of $10^5 M^{-1} s^{-1}$, which is more than 3000 times faster than unsubstituted dimedone and 5 times greater than free Cys (236, 286). Care should be taken when using this reagent, as exposure to air for prolonged periods of time can turn TNB into 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), which may react with free Cys (228).

Lastly, a chimeric tool that measures sulfenyl binding partners in cellular models has been developed using an 85 AA portion of the Cys rich C-terminal portion of YAP-1, which is a *Saccharomyces cerevisiae* transcription factor known to form a sulfenyl adduct. Its specificity was determined using an inhibitory assay with dimedone (276). The proteomic identification of sulfenylation is typically based on the specific reduction of sulfenic acid with arsenite or the specific labeling of sulfenic acid by dimedone (72). With these approaches, multiple cardiac proteins, including cytoskeletal components, undergo sulfenylation after exposure to H_2O_2 , as detected by matrix-assisted laser desorption ionization time of flight mass spectrometer (MALDI-TOF) analysis (241). Labeling with dimedone has allowed for both improved detection for

protein enrichment (46) and evaluation of sulfenylated proteins using more highly cell permeable azide-linked analogs, such as DAZ-2 by LC-MS/MS (160). In addition, novel isotope-coded dimedone and iododimedone have been applied in the quantitative analysis of sulfenic acid modifications with the use of LC-MS (247).

S-Glutathionylation and disulfides. In addition, Cys can lead to the formation of intra- or intermolecular disulfides and mixed disulfides [S-glutathionylation; see review for further info (215)]. Interestingly, RSNO has been postulated to form glutathione-mixed disulfides and may act as an intermediary for S-glutathionylation. S-glutathionylation, inter- and intramolecular disulfides can occur under RSOH formation, enzymatic disulfide formation, thioltransferase activity from oxidized glutathione (GSSG) to a thiolate, sulfenylamide bond interactions with reduced glutathione (GSH), and condensation of GSSG to a glutathione disulfide S-oxide. Enzymatic disulfide formation has been reported for glutathione S-transferases (GST), ERV1, sulfhydryl oxidases, protein disulfide isomerase (PDI), and glutathione peroxidases (88). Glrx-1 specifically reduces glutathione-mixed disulfides in the presence of NADPH and glutathione reductase; while Trx and PDI reduce intra-intermolecular disulfides (163, 238). These modifications are detected with the use of labeling techniques as reviewed (215). The methods used to look at oxidative changes of thiols generally rely on creating derivatives with iodoacetamide, maleimide, and thiosulfates because of their tendency to alkylate thiol groups selectively (67). Labeling can be carried out in several ways: The first is using tagged alkylation of free thiols and determining the reduction of tagged labeling, which would be indicative of oxidation. The second involves the alkylation of free thiols with subsequent reduction of the initially oxidized thiols and re-labeling with a labeled alkylation agent, be it with fluorescent, biotin, isotopic, or radioactive tags (95, 303). An increase in tagged labeling is indicative of increased oxidation.

Some other approaches include utilizing (127) activated thiol sepharose to enrich thiol-containing proteins, eluting with a reducing agent, and separating by 2DE to visualize the difference between samples. The problems with these techniques are the specificity of the reducing agents, as they can reverse other Cys modifications such as S-palmitoylation and cannot distinguish between a mixed disulfide and an intramolecular disulfide. More novel glutathione analogs that specifically identify thiol-modified compounds are being used as well to detect S-glutathionylation (31, 67, 270, 308). An antibody is also available but was limited by its sensitivity with differing specificity for glutathione adducts on different proteins, and, therefore, large quantities of a particular S-glutathionylated protein may be required for detection (215). The proteomic detection of S-glutathionylation has been accomplished by either direct or indirect means. The former utilizes a reactive thiosulfanate to initially block free thiols and LC-MS/MS to determine a 305 Da shift that would be suggestive of protein-SG formation. This method has been used for individual proteins but not for a whole proteome analysis. Indirect measurements of S-glutathionylation uses an initial labeling step with a thiosulfanate, a subsequent reduction of the mixed disulfide by glutaredoxin (Glrx) and, finally, labeling with biotinylated *N*-ethylmaleimide or other thiol tags. Measurements of intermolecular

disulfide formation have been performed with diagonal gel electrophoresis (32). The principle of this method is that proteins with intermolecular disulfides move away from the diagonal protein band as a result of a shift in the molecular weight, geometry, and charge under reducing conditions. Generally, samples are first separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis under nonreducing conditions, and then, the whole lane is excised and further separated under reducing conditions in the second dimension. Distinct protein spots are then analyzed by LC-MS/MS for an evaluation of protein modifications.

The *in vivo* effects of S-glutathionylation are probably best assessed in *Glrx* knockout mice, which have worsened ischemia reperfusion injury in the cardiovascular system (124). In contrast, it appears that the effects of angiotensin II (Ang II) infusion on cardiac and aortic medial hypertrophy are inhibited by *Glrx* deletion (15). This effect is attributed to attenuation of NOX activity by interference of upstream signaling components. Alternatively, the effects of overexpression of Trx, which reduces sulfenic acid, S-nitrosylation, and intramolecular disulfides but not mixed disulfides, inhibits Ang II infusion by regulating mir-98 (307). Similarly, the overexpression of Trx2 also inhibits Ang II-induced vascular and cardiac hypertrophy with decreased mitochondrial RNOS production (300). Whether these effects are due to a change in mitochondria to nuclear signaling needs further evaluation. Lastly, deletion of Trx leads to the potentiation of pressure overload hypertrophy and is thought to be secondary to changes in histone deacetylase 4 (HDAC4) disulfide formation at sites 667–669 (7, 305).

Sulfinylation and sulfonylation. Two other Cys thiol modifications include sulfinylation and sulfonylation. Sulfinylation is reversible with sulfiredoxin; but the only protein known to have a reversible sulfinyl group is peroxiredoxin (233). The last modification, sulfonylation, is a completely irreversible modification that is widely present on SERCA2 in cardiovascular pathologies, as identified with a site-specific antibody (281). Recent methods have been described as selectively enriching the quantity of sulfopeptides such as Cys sulfonic acid. Similar to other acidic peptides, a sulfopeptide shows inefficient ionization in MALDI-MS and electrospray ionization (ESI)-MS (230). Given these difficulties, several methods have employed ammonium salts (148) or basic polypeptides to improve the isolation of acidic peptides. Wu and colleagues (45) have used polyarginine, which is known to bind to sulfonate groups, as a complementary ligand. After affinity ionic capture had been performed using polyarginine-coated nanodiamonds, the peptides from a complex mixture of proteins were analyzed by MALDI-TOF-MS (45), and the particles demonstrated a propensity for peptides binding to multiple sulfonic acid residues. This technique would allow for further evaluation of the sulfonic acid sub-proteome.

Methionine

Met, similar to Cys, is another amino acid that contains a sulfur group at its side chain and is sensitive to oxidative changes by either a one- or two-electron oxidation. The former will produce a methionine sulfoxide by direct oxygen transfer from an RNOS, while the latter produces a disulfide cation

that can then react with H_2O to result in methionine sulfoxide (244, 294). The oxidation of Met alters its hydrophobicity, which can lead to conformational changes that affect protein-protein interactions or enzymatic activity (266). Two distinct stereoisomers are formed around the sulfur-S- and R-epimers, and these are reversed by methionine sulfoxide reductase A (*MsrA*) and B (*MsrB*), respectively (99, 195–197). *MsrA* can also act independently of redox signaling as an S-epimer oxidase (164). The reducing equivalents needed for this reaction are provided by the Trx system. Protein carbonyl adducts had been used as a marker for methionine sulfoxide modifications, as the current assumption is that the structural changes associated with sulfoxidation increase the likelihood of further modification and promote protein carbonyl formation (195). Recently, antibodies to methionine sulfoxide have been developed and demonstrate increased Met oxidation in the cardiac tissue after treatment with an oxidant (206). The measurement of Met modifications has been difficult due to their chemical instability, detection methods that inadvertently reduce Met oxidation, and a sample preparation that can introduce additional artifacts, as quenching cations and heavy metals are necessary to prevent the formation of spurious RNOS in the isolation procedure (34). MS techniques have been developed for detecting methionine sulfoxides (34, 102, 103, 126). Methionine sulfoxide in acid-labile and protective carriers such as methane sulfonic acid or chemical derivatization such as by CNBr cleavage are necessary to preserve this modification. The latter technique is frequently used and involves CNBr cleavage of Met on the carboxyl side of the amino acid, but if a methionine sulfoxide is present, then this cleavage can no longer occur. These methionine sulfoxide residues can be detected by MS as a 16 Da shift (126, 299) and a missed peptide cleavage. However, the interassay variability of chemical modification by bromination can differ by approximately 20% (34). Another technique that has been used is collision-induced dissociation (CID) and tandem MS, which along with gas-phase fragmentation can determine the sequence and position of methionine sulfoxide. During this procedure, a specific 64 Da loss from the product precursor, methane sulfenylate (CH_3SOH) occurs that is unique to methionine sulfoxide and helps differentiate between phenylalanine (Phe), which has the same mass of 165 Da. The problem with this method is that only small peptides can be evaluated (132, 242). The use of this technique in combination with electron capture dissociation (ECD) allows for improved detection of slightly more complex peptide mixtures (103). One last method for methionine sulfoxide detection utilizes combined fractional diagonal chromatography (COFRADIC) with SILAC and a subsequent analysis by LC-MS-MS. Ghesquiere *et al.* have described more than 1600 modified proteins from H_2O_2 -treated Jurkat cells using SILAC and 27 protein methionine sulfoxide modifications in serum from a mouse sepsis model using the COFRADIC technique alone. Interestingly, the sulfoxide modifications appear to have occurred more commonly near polar groups on proteins (91).

MsrA knockout mice were initially observed as having a prolonged life span, but subsequent studies were unable to confirm this result and found the mice to be more susceptible to oxidative stress (194, 240). In the cardiovascular system, these *MsrA* knockout mice were found as having lower sarcomeric shortening and peak calcium transients in cardiomyocytes along with larger mitochondria (201). In addition, *MsrA* is

necessary for preventing further ventricular remodeling post-infarct, as it counteracts the oxidation and activation of calmodulin kinase II (CaMKII), which controls postinfarct apoptosis and aldosterone-mediated matrix remodeling (74, 311).

The complimentary enzyme *MsrB* is composed of three subtypes: B1, which is located in the cytosol and the nucleus; B2, which localizes to the mitochondria or endoplasmic reticulum; and B3, which is solely located in the endoplasmic reticulum (1, 143). Although there is an up-regulation of *MsrB1* in cardiac hypertrophy (125), the *MsrB1* deletion animal shows no cardiac pathology or increases in cardiovascular protein oxidation at baseline (81). With regard to human pathology, loss-of-function mutations of *MsrB3* are associated with deafness (8), but no connection has been made to CVD. Further studies involving models of cardiovascular pathology and *MsrA* are required to delineate the role of Met oxidation. Interestingly, while reduction may be carried out directly by thionein for *MsrB2* and B3, the effects of *Msr* proteins are highly dependent on Trx, and, thus, Trx deletion or overexpression may indirectly influence Met oxidation as well (113, 144, 239). Further oxidation of methionine sulfoxide may form sulfone (RSO_2CH_3), which is irreversible and damaging.

His and Lys

His and Lys are the two most reactive amino acids that undergo metal-catalyzed oxidations (Fe^{2+} or Cu^{2+}/O_2 /ascorbate). His forms 2-oxo-histidine and can undergo another oxidation reaction to produce ring-opened products such as aspartate, aspartylurea, and formylasparagine. 2-oxo-histidine occurs *in vivo* on MnSOD (136), which alters its activity, and regulates PerR, a metal-dependent sensor of H_2O_2 in *Bacillus subtilis* (282). On the other hand, Lys is subject to substantial post-translational modifications, including acetylation, methylation, SUMOylation (small ubiquitin-like modifier), and ubiquitination. These post-translational modifications have been shown to control cellular signaling and protein degradation. Oxidative modifications have been proposed to affect these modifications, thus interfering with signaling functions (135). Lys can react to form allysine (adipic semialdehyde) in a metal-catalyzed oxidation (Cu^{2+}/O_2 /ascorbate) that occurs in tissue culture after treatment with high glucose (232) and is increased in the human lens with both aging and diabetes (76). His and Lys side chains can also react to form protein carbonyls. One significant difference between the two in-forming protein carbonyls is that histidine, similar to Arg and proline, forms aldehydes, while the Lys oxidation product, adipic semialdehyde leads to direct carbonylation. The reader is referred to several recent excellent reviews for further information on this topic (18, 195, 302). Carbonylation has been detected by antibodies, enrichment-labeling techniques, and mass spectrometry (271). The antibody utilizes the reactivity of carbonyls to 2,4-dinitrophenylhydrazine (DNPH) and measures the conjugates of DNPH with proteins. In addition to DNPH, labeling can be performed with biotin hydrazide, Girard's P reagent, or oxidation-dependent, element-coded affinity tags and coupled with MS for identification or in the case of biotin, hydrazide immunoblotting. Protein carbonylation may lead to changes in signaling and function and could be used as an oxidative biomarker. In a rat model of diabetes-induced cardiovascular dysfunction, the

carbonylation of SERCA2a at specific Lys residues inhibits enzymatic activity (253) and the cardiac contractile proteins myosin heavy chain α and β were carbonylated, which was associated with a decline in cardiac inotropy (254). A recent work demonstrates that endothelin-1 selectively increases carbonylation of the annexin A1 protein (257) in smooth muscle cells, leading to increased proteosomal degradation of the receptor and subsequent cellular growth. In addition, protein carbonylation has been used as a general marker of protein oxidative damage in Alzheimer's disease, cystic fibrosis, diabetes, and systemic amyloidosis (59). In the cardiovascular system, ischemic injury has been noted to increase carbonyls in both coronary bypass surgery patients and post-infarct patients (210) and (190). Interestingly, heart failure patients were found to have a 10-fold increase in protein carbonyls in their plasma (39). Lastly, these two amino acids can undergo a reaction with lipid aldehydes, which are covered in detail in the section entitled lipid peroxidation-derived electrophilic aldehydes.

Tyr and Phe

The aromatic phenol side chain of Tyr characterizes the hydrophobic and fairly unreactive nature of this amino acid. Tyr residues are well-studied components of receptor Tyr kinases that are important in cancer biology, and their oxidative modifications during CVD is a growing area of research. Tyr forms a tyrosyl radical at the active site of cyclooxygenase, initiating the controlled peroxidation of arachidonic acid to prostaglandin G_2 (284). Various oxidative modifications have been reported for Tyr, including hydroxylation to form 3,4-dihydroxyphenylalanine, often referred to as protein-dihydroxyphenylalanine (DOPA), (92) as well as ortho-quinones, nitration (212, 272), dityrosine-forming intraprotein and interprotein crosslinks, and halogenation such as chlori- and iodination. Halogenation is catalyzed by peroxidases occurring under physiological conditions in the thyroid follicle during the synthesis of the thyroid hormones thyroxine-3 and -4 (T3, T4). Thyroglobulin, a Tyr-rich protein, is released into the luminal colloid and a specialized NOX (dual oxidase [DUOX]), which also contains a peroxidase domain, reduces I^- to iodine and iodines Tyr residues in thyroglobulin. It should be noted that Tyr iodination may be artificially produced while working up samples for proteomic analysis, and can be observed when blocking Cys with decomposed iodoacetamide (brownish color). Furthermore, chlorination and nitration of Tyr residues occurs during inflammation and is mainly catalyzed by myeloperoxidase, but other peroxidases can also mediate this reaction. Nitration, however, is also mediated by peroxynitrite (PN), an RNOS that is formed in the reaction of nitric oxide with superoxide. At low concentrations, this reaction requires enzymatic catalysis, which has also been observed with prostacyclin synthase or manganese SOD. Interestingly, reports have suggested the existence of a reducing denitrase enzyme, but the protein has yet to be identified (2, 129, 138, 257). Nevertheless, nitration should be analyzed with caution, as acid-catalyzed nitration from nitrate *via* a nitrosotyrosine intermediate has been reported as a freezing artifact, and nitration might occur post-mortem when acidosis is apt to reduce nitrite in tissues. By virtue of the phenolic group, the Tyr residues can also form tyrosyl radicals by reacting with RNOS that in a radical-radical reaction leads to dityrosine formation and crosslinks (104). The

hydroxylation of Phe is a well-known reaction that leads to Tyr formation, and subsequent hydroxylation of Tyr leads to DOPA formation. These reactions are either catalyzed with free amino acids by specialized mixed functional monooxygenases (Phe and Tyr hydroxylase) or can be caused by very reactive species, including the hydroxyl radical or PN.

The detection of Tyr and Phe oxidations has been challenging, as RNOS reactions produce a variety of modifications, including nitrotyrosine, dityrosine, DOPA, hydroxyl ortho-, and meta-Tyr (96, 156, 235). Nitrated proteins can be probed for with various commercially available antibodies, but detection is problematic and should always be confirmed by a reduction of nitrotyrosine to aminotyrosine with dithionite. Since the quantity of these modified amino acids can be quite low, nitrated proteins have been enriched using anti-nitrotyrosine antibodies (204) followed by a partial transfer of 2DE separated proteins with MALDI-TOF and ESI-MS/MS identification of the sites (2, 139, 140). Using this method, Kanski *et al.* have shown that nitration appears to increase in metabolic proteins during cardiac aging. Amoresano *et al.* (11) have developed an assay called reporter ion generation tag (RIGhT) for the detection of nitrotyrosine-containing proteins (10). This method involves the selective modification of nitrotyrosine to dansylaminotyrosine using dansyl chloride and then monitoring proteins by generating specific ions that are unique to dansyl derivatives by MS. Another quantitative proteomics approach to detect 3-nitrotyrosine developed by Sharov *et al.* (255) is based on the selective reduction of 3-nitrotyrosine to 3-aminotyrosine. The reduced modification is then labeled with a fluorescent tag in a reaction with 4-(amino-methyl) benzenesulfonic acid.

Dityrosine can be detected in a sensitive and quantitative way by the use of mass spectrometry (63, 207). Furthermore, most other modifications of Tyr and Phe are relatively stable and can be detected using high-performance (pressure) liquid chromatography (HPLC), GC-MS, and LC-MS-based methods.

In contrast to nitrotyrosine modifications, the other protein Tyr oxidation products have only been analyzed by MS due to the fact that no antibodies have been developed for their evaluation. 3-Chlorotyrosine is a stable oxidative Tyr product derived from myeloperoxidase, and has been identified as a modification of ApoAI from high-density lipoprotein cholesterol using LC-ESI/MS/MS (252).

Tryptophan

Tryptophan (Trp) can be oxidized to hydroxytryptophan, dihydroxytryptophan, N-formylkynurenine (NFK), and kynurenine (KYN). A hydroxyl radical can interact with the aromatic nucleus of Trp, and in the presence of Fe, forms hydroxylated Trp at the 4, 5, 6, and 7 positions in the ratio of 4:2:2:3. 5-hydroxytryptophan, which can be enzymatically formed in the presence of tetrahydrobiopterin and Trp hydroxylase, is a precursor to serotonin (181). Using 500 μM to 1 mM H_2O_2 , hydroxytryptophan modifications can be induced in cytochrome C oxidase, subunit 1 (158). Other oxidation end-products of Trp include NFK and KYN, which are formed after a direct interaction with 1O_2 , or ozone (70). Two other radical reactions by which NFK and KYN can be formed are (i) the Trp radical interacting with superoxide to form Trp hydroperoxide and (ii) the Trp radical interacting with molecular oxygen, leading to a Trp peroxy radical. The

tryptophan hydroperoxide and Trp peroxy radical can be rearranged to form NFK and KYN (70). Similar to some amino acids such as Met, Trp may also theoretically act as a long-range electron transfer shuttle between other amino acids such as Tyr and Cys, which would allow for the formation of tyrosyl and thiyl radicals, respectively, on the peptide backbone (256). Antibodies have been designed for the detection of NFK on protein side chains (70, 267), but MS detection suggests that oxidized Trp products can sometimes be a result of artifacts, as they have been observed with proteins isolated by gel electrophoresis, but not with in-solution digests (214).

LC-MS has identified oxidation products of Trp in the serum in association with atherosclerosis and in cardiac and skeletal muscle tissue (78, 108). Several of these modified proteins include actin, troponin, H-FABP, and complex V. However, due to the multiple isomeric oxidative degradation products (e.g., serotonin or 5-hydroxytryptamine [5-HT] and oxyindolylalanine) that occur, it has been difficult to distinguish these in a complex protein mixture. Hoffman and colleagues (280) have shown that by using high-energy ESI-CID with isolated peptides, the differences in masses within a given ion series and specific marker ions could differentiate the isomeric forms of 5-HT and oxyindolylalanine. This suggests that in complex protein mixtures, the possibility of identifying these isomeric forms is feasible.

KYN has been proposed as a direct endothelium-derived relaxing factor that is produced during inflammation (295). The oxidation of this amino acid has also been suggested as playing a role in atherosclerosis, as KYN has been identified in oxidized low-density lipoprotein and apolipoprotein B (apoB)-100 (205, 306). Patients with coronary heart disease may have an elevated ratio of KYN: Trp in the serum, which could function as a potential oxidative stress biomarker of disease (142, 211). KYN also seems to lower the mitochondrial ATP synthesis by significantly increasing state IV respiration, and reducing the respiratory control index and adenosine-5'-diphosphate (ADP)/oxygen ratio of glutamate/malate-consuming heart mitochondria (17). Human heart mitochondrial proteins have these oxidative modifications of Trp without pathology (278), and whether this can act as a means of controlling the ATP/ADP ratio is unclear and requires further investigation. Although oxidatively modified Trp residues are generated in some CVDs, no direct evidence exists to prove the role of Trp oxidation in causing cardiac pathology.

Lipid peroxidation-derived electrophilic aldehydes

This diverse series of α,β -unsaturated aldehydes (Fig. 5) is derived from endogenous lipid peroxidation, xenobiotic metabolism, food, or environmental pollution (209). Members of this group include acrolein (217), which is the most reactive molecule, and prominent lipid peroxidation products such as HNE (37) and MDA (75). RNOS can interact with polyunsaturated fatty acids and initiate lipid peroxy radicals that lead to a radical chain reaction. Usually, the cellular antioxidant system, which includes the lipid soluble vitamin E, quenches these radical chain reactions. However, lipid peroxidation can occur either under inflammatory conditions or during the reperfusion phase after ischemia/anoxia. This is often accompanied by an increase of free Fe in the cell, catalyzing Fenton-like reactions, further potentiating oxidative stress. Enzymatically catalyzed reactions, such as myeloper-

oxidase or cyclooxygenase in the presence of RNOS, can also efficiently peroxidize polyunsaturated fatty acids. The decomposition of lipid peroxy radical species generates various α,β -unsaturated aldehydes by β -cleavage (cleavage at the second carbon atom). The toxicity of these compounds is mainly based on their reactivity with proteins and peptides to form a stable adduct, but DNA modifications (mutagen) and the depletion of cellular reducing equivalents, including glutathione, may also contribute. The cellular detoxification of reactive aldehyde occurs either by glutathione S-transferase-catalyzed phase II conjugation reactions or aldehyde dehydrogenases.

The α,β -unsaturated aldehydes (Fig. 5) are comprised of an aldehyde group that forms a conjugated system with the β -double bond, thus withdrawing electrons from the β -double bond (π -electrons) which forms a soft electrophile (electron-deficient species) on the C-atom (asterisk). This effect can be further enhanced by neighboring electron withdrawing groups such as the hydroxyl group in HNE. Chemistry suggests that soft electrophiles preferentially react with soft nucleophiles (electron-rich species), including the thiolate of Cys. The soft electrophiles conjugate the reactive aldehyde at its electrophilic center to the nucleophilic moiety of the amino acid; this reaction, termed the Michael adduct, is named after Arthur Michael. In contrast, strong nucleophiles, including the imidazole moiety of His or the ϵ -amino group of Lys residues, will react much slower. Therefore, the following general sequence of reactivity for amino-acid side chains is generally observed: Cys > His > Lys > Arg. However, vicinal amino acids, as mentioned earlier, can greatly affect this reaction by steric interference or by modulating the nucleophilicity of the side chain moiety. The Michael addition leaves the aldehyde group intact, which can either further undergo cyclization or react in a Schiff base reaction with amino moieties of neighboring amino acids, leading to intra- and intermolecular crosslinks. The complex chemistry of α,β -unsaturated aldehydes illustrates the multitude of protein modifications and the intricacy that arises for MS analytics. Currently available search algorithms can at best map simple adducts but are unable to identify inter- and intramolecular crosslinks and cyclization reactions.

HNE, which is the most studied α,β -unsaturated aldehyde, was first observed in peroxidized liver microsomal lipids as the major cytotoxic lipid peroxidation byproduct (23) and has since been observed in the serum (145), brain (193), kidney (134), and the heart (69). An early method used to identify the targets of HNE modification was the spectrophotometric detection of a 2,4-dinitrophenol (DNP) derivative that reacts with carbonylated proteins (159, 161). Other carbonyl reactive probes, such as biotin-linked hydrazide (121), allows for identification by mass spectroscopy and electrochemical detection of proteins that are oxidatively modified *in vitro* (188) or *in vivo* (100, 259). The major limitation of these methods is the nonspecificity of hydrazide and 2,4-DNP (54), which can react with other aldehydes (*i.e.*, MDA) and the possibility that native biotin-containing proteins can be extracted with the biotin pulldown (20). To increase the specificity of using hydrazide labeling, carbonylated proteins isolated using biotin hydrazide can then be enriched using stable isotope labeling (185). Immunochemical detection of HNE-proteins has been used with antibodies specific to the His and Lys dihydropyrrrol HNE adducts (285, 288). The antibody specific for

HNE-bound His has identified cytochrome c oxidase modifications in the rat heart subjected to ischemia/reperfusion (49), and the HNE-Lys antibody has detected modifications of mitochondrial subunits in the diabetic rat heart (153). Antibody detection is sufficient to demonstrate the presence of HNE, but these antibodies lack specificity and may detect other Michael adducts such as 4-hydroxy-2-decenal and 4-hydroxy-2-octenal (288, 289). To obviate these shortcomings, experiments with azido or alkynyl-derivatized HNE coupled with biotin click chemistry could be utilized to investigate proteins that have a propensity for modification (293). To determine endogenous HNE adducts, enrichment techniques should be used with either antibody-bound sepharose (79) or biotin hydroxylamine or hydrazide to selectively isolate Michael adducts (47, 225). The problem with each of the latter techniques is that both of these compounds react with all carbonyl adducts. Other lipid-derived aldehyde species, including carbonyls and acrolein adducts, have been identified during CVD states and may even mediate cellular signaling (274).

GC-MS has been used to detect HNE-adducted products when applied to human plasma (179, 184, 260) as well as urine (246), although more accurate methods have been performed with other MS methodologies to obtain peptide sequence information. By incorporating labeling probes, reverse-phase chromatography MS/MS has been used to identify modified-adducted proteins in adipocytes (100). Using an ICAT reagent that is linked to a hydrazide functional group, differential labeling with light and heavy carbon identified HNE-modified cardiac mitochondrial proteins by reverse-phase chromatography coupled with MALDI-MS/MS (110). A similar means of identifying carbonylated skeletal muscle mitochondrial proteins used biotin-hydrazide enrichment and iTRAQ labeling with LC MS/MS (185). Furthermore, an MALDI-TOF/MS analysis of mouse myocardium treated directly with the unsaturated aldehyde acrolein was found to have several carbonyl-modified proteins (172). Recently, methods that required no enrichment strategy were described for *ex vivo* HNE-treated mitochondrial proteins using a neutral loss- MS^3 on a hybrid linear ion trap-Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT) that identified histidine-modified HNE peptides (269). In this protocol, neutral loss of HNE is observed on the MS/MS of HNE-modified peptides, thus triggering MS^3 analysis of the neutral-loss product ion to reveal the sequence of the peptide. By coupling this with ECD-fragmentation, retention of the HNE adduct on the product ions is feasible for identification, and, thus, may be a more meaningful peptide fragmentation than CID fragmentation-based MS/MS analysis (170, 176, 192, 227). Lastly, the use of electron transfer dissociation fragmentation may improve the detection of HNE modifications and may be superior to CID in the characterization of modification sites due to the production of c and z ions (85, 226).

Pathophysiological concentrations of HNE have been reported to range from 0.3 to as high as 10 μM in tissues (246), but the cumulative oxidative effects of HNE may be underappreciated, as it can induce peroxide formation (266) and mitochondrial-derived ROS (151) at doses as low as 10 μM . In patch-clamp studies, isolated cardiac myocytes perfused with supra-normal concentrations HNE were shown to undergo membrane depolarization and loss of excitability (28). Other works using high concentrations concluded that HNE can induce intracellular calcium overload in cardiomyocytes

(200). At 40 μM , HNE induces adducts that inhibit the tumor suppressor protein LKB1 to promote signaling changes which are indicative of myocyte hypertrophy (64). At high physiologic levels of HNE (10 μM), transient treatment (1–3 h) increases both oxygen consumption and glycolysis, while sustained HNE treatment (8–16 h) greatly reduces cell viability (123). At 5 μM , HNE activates the oxidant-sensitive Nrf2 transcription factor in cardiomyocytes (310) and can protect against further oxidative injury by increasing GSH content through its modifications of glutamate-Cys-ligase, the rate-limiting enzyme in *de novo* GSH biosynthesis (16).

Detoxification of free HNE involves either oxidation by aldehyde dehydrogenase (primarily the mitochondrial isoform, aldehyde dehydrogenase 2 [ALDH2]) (229) or reduction by aldose reductase (AR) (261). A single nucleotide polymorphism of ALDH2 (E504K) first identified in Asian populations inactivates ALDH2. Since ALDH2 functions cooperatively as a homo- or heterotetramer, all tetramers that contain 1 or more mutated subunits are functionally inactive. In a transgenic loss-of-function mouse model, overexpression of E504K-ALDH2 significantly increased HNE adduction of mitochondrial proteins (73). Similarly, AR-deficient mice fed a high fat diet exhibit increased plasma HNE adducts, advanced glycation endproducts, and acrolein formation (13). Interestingly, the loss of AR had no effect on HNE adduct formation in mice fed a chow diet, suggesting that lipid peroxide accumulation may be minimal or readily detoxified by other mechanisms under physiological conditions.

From these studies, the quantity of HNE used and the treatment duration are critical parameters to be considered when studying the signaling changes induced by HNE. When assessing the effects of HNE on cellular signaling, it is suggested that investigators use pathophysiologically relevant doses of HNE ($\leq 10 \mu M$) for short-term treatments (≤ 2 h). Furthermore, since low doses of HNE can initiate RNOS production, the possibility of RNOS-mediated effects needs to be addressed. All these studies have used exogenous sources of HNE to study its effect on signaling, but a system by which HNE is endogenously produced would be more pathophysiologically relevant in determining its biological role. With such a system, the localized concentrations of HNE produced would be more likely to reflect native cellular signaling events induced by this species.

Analytics of OPTMs

Several methods exist for the detection of OPTMS. These can range from antibody detection, UV-vis evaluation, labeling techniques for enrichment, and mass spectrometry. Each of these methods have their strengths as well as weaknesses for analyzing complex mixtures of proteins. OPTMs have been detected using chemical labeling or antibodies raised against specific oxidative amino-acid modifications (see Table 3 for specific OPTMs). Antibodies allow for a rapid evaluation of a large number of proteins and samples using either protein electrophoresis, enzyme-linked immunosorbent assays (ELISA), immunoblot, or immunohistochemistry. However, several of the available antibodies that study oxidative modifications suffer from the lack of specificity (52, 214, 215). To overcome this, several OPTMs are evaluated *via* selective enrichment techniques using compounds or peptides with a high specificity to the oxidized amino acids. Examples of these

include anti-DNPH antibodies used in labeling carbonyls and reactive thiolsulfonates used in labeling Cys. These allow for the detection of lower quantities of modified peptides but do not directly measure the modification (*e.g.*, *S*-nitrosylation, *S*-glutathionylation, or sulfenylation will all change thiolsulfonate binding). In addition, if an affinity tag is used, then protein complexes may be bound to the affinity column that is not necessarily oxidized (234). Another method used to detect oxidative modifications in proteins includes changes in UV-Vis spectra. Although the utilization of a spectroscopic analysis of protein modification has been used for isolated proteins in solution, it would work poorly for complex mixtures. The final technique is mass spectrometry which allows for a direct detection of the peptide residue affected by oxidant modification. Several limitations of mass spectrometry exist, however, and include inadequate peptide digestion, multiple PTMS that make database mining difficult to achieve, incomplete and variable databases, low-abundance proteins, and environmental contamination. The reader is referred to an excellent review (171) on this topic. Similarly, our experience while identifying OPTMs has shown that (i) the proportion of oxidatively modified protein is small in relation to the unmodified form and both should be compared and reported; (ii) OPTMs occur on multiple sites delivering complex signals that result from the modified digestion of the protein due to an adduct that precludes fragmentation; and (iii) there can be multiple modifications on a single tryptic peptide. These factors are not taken into consideration by many search algorithms, and as a result, these modifications are missed due to low confidence. Moreover, some oxidative modifications on, for example, Lys, may result in a missed cleavage with trypsin, which might make identification of the tryptic peptide difficult due to the increased peptide length. We have found that a combination of manual and computer-aided searches are necessary for the adequate identification of peptides. This may help explain a lack of reproducibility and, at times, a general inability to identify standardized samples among MS laboratories, even though peptide identification for the correct proteins is present (22). Despite these limitations, this technique has very sensitive detection capabilities and is a potent platform for the analysis of multiple types of OPTMs simultaneously. Readers are referred to the following reviews for a more in-depth description of mass spectrometry (6, 56, 57, 268, 309).

The overall workflow of MS-based proteomics for biomarker discovery is depicted in Figure 6, and first involves protein extraction from cells or tissue. The conditions of extraction and choice of buffer are crucial, as a sample preparation might produce artificial oxidation (150). In fact, appropriate storage is also a concern for the evaluation of oxidative modifications. For example, carbonyls are noted to undergo Schiff base reactions with Lys even at -80°C ; thus, the quantities of the modification may lessen over time. It is unclear whether other OPTMs are changed after storage, and ideally, samples should be used immediately. After extraction, the proteins are digested using specific proteases (*e.g.*, trypsin or chymotrypsin) in solution or after gel isolation. Although trypsin is the most commonly used enzyme for digestion, some proteins do not fragment well with this enzyme and result in a reduced protein sequence coverage. In addition, the oxidation of Lys and Arg residues may interfere with tryptic digestion and cause missed cleavages, resulting

in larger MS fragments. Using different enzymes such as Glu C or chymotrypsin in conjunction with trypsin may allow for a better coverage. Enrichment and fractionation using different approaches such as HPLC with reversed phase, strong cation exchange, or hydrophilic interaction LC produces a purer fraction for MS analysis. The list of mass peaks can then be evaluated on search engines such as Mascot or Sequest, where they are compared with theoretical masses generated from protein databases. By comparing this information, the analysis can provide information on the amino-acid sequence and modifications on that peptide (65, 268).

OPTMS As Biomarkers in Humans

Due to their sheer quantity and proximity to oxidant sources, proteins are a principle target of RNOS and may be a part of the antioxidant cellular defense system (117, 162, 173, 231). This direct effect of RNOS allows for the accumulation of oxidative modifications over the protein's lifetime. Theoretically, these can be used as specific biomarkers in human disease. Although oxidation affects both the protein backbone and amino-acid side chains, an *in vivo* analysis of back bone fragmentation is limited due to the presence of proteases and peptidases, which could lead to protein or peptide cleavage and produce variable peptides, thereby further increasing the complexity of *in vivo* mixtures (219). Therefore, a potential oxidative biomarker should be based on changes to the amino-acid side chain groups. In searching for an oxidative marker, a stable, nonenzymatic, and irreversible modification would be preferred, as adequate absolute quantification of protein oxidation could be performed. Thus, oxidative side-chain modifications that could undergo further modification or can be enzymatically produced, such as carbonyls and lipid peroxidation products, would be difficult to quantify during progressive disease states and may not be the ideal biomarker. For example, protein carbonyls are initially formed under metal-catalyzed oxidations, can undergo further modification, act as a signal for protein degradation, and have also been suggested as being a reversible enzymatic modification. Thus, the levels of carbonyls measured may vary depending on their further reactivity, cellular antioxidant status and detoxification capacity, and presence of degradative enzymes (177). These factors would indicate that the carbonyl content may be in constant flux, and, therefore, would not reflect the total oxidative state of the cell. By extension of this logic, other reversible OPTMs may also undergo fluctuations in their levels and could not reliably be used to quantify the total oxidative state of the organ. We will review the most likely R-group oxidative modifications that may reasonably comprise an oxidative biomarker.

The R-groups include the aliphatic, aromatic, amidic, acidic and basic amino acids. Aliphatic amino acids, which include Gly, Ala, Val, Pro, Leu, and Ile, form alcohols, peroxides, or carbonyls. Amidic, Acidic, Basic, and hydroxylic amino acids can lead to carbonyl groups. In the case of Lys, hydroxylation or adipic aldehyde can be generated, but both these can be generated enzymatically as well. The sulfur-containing amino acids, Cys and Met, form reversible modifications that may rely on factors other than radical flux in determining its quantification, and this is partially due to the presence of Cys and reductive enzymes. However, the irreversible Cys, sulfinic and sulfonic, and methionine sulfone oxidation

TABLE 3. REDOX-SENSITIVE PROTEINS IN THE CARDIOVASCULAR SYSTEM AND THEIR OXIDATIVE MODIFICATIONS

Serial no.	Name	Modification (site if known)
1	2-oxoglutarate dehydrogenase	S-Nitrosylation (51)
2	3-oxoacid CoA transferase 1	Sulfenylation (46)
3	14-3-3 protein epsilon	S-Nitrosylation C ¹⁹² (38)
4	14-3-3 protein eta	S-Nitrosylation C ¹¹² (38)
5	14-3-3 protein zeta/delta	S-Nitrosylation C ⁹⁴ (38)
6	Aconitase 2	S-Glutathionylation C ¹²⁶ , C ³⁸⁵ (86, 111)
		S-Thionylation (68)
		Sulfenylation (46, 241)
		S-Nitrosylation (51)
		Sulfonylation C ¹²⁶ , C ³⁸⁵ (86, 111)
		Tyr-Nitration Y ¹⁵¹ , Y ⁴⁷² (111)
7	Actin	Sulfenylation (241)
		Disulfide (42)
		S-Thionylation (68, 241)
8	ADP, ATP carrier protein T1	Sulfenylation (241)
9	Aldehyde dehydrogenase 2, mitochondrial	S-Nitrosylation (51)
10	Alpha-actinin-2	Sulfenylation (46)
11	Acyl-CoA dehydrogenase	Sulfenylation (241)
		Disulfide (32)
12	Argininosuccinate synthase	S-Nitrosylation (248)
13	ATP synthase	Sulfenylation (46, 241)
		Disulfide (32)
14	Arginase-1	S-Nitrosylation (248)
15	Aspartate aminotransferase	Sulfenylation (241)
16	Apolipoprotein B-100	KYN (205)
17	Apoptosis regulator Bcl-2	S-Nitrosylation (248)
18	Beta-arrestin-2	S-Nitrosylation (248)
19	Beta-Melanocyte-Stimulating Hormone	Methionine sulfoxide (103)
20	Calcium/calmodulin-dependent protein kinase type II	S-Nitrosylation (248)
21	Calmodulin	Tyr-Nitration (257)
22	Caspase-3	S-Nitrosylation (248)
23	Caspase-9	S-Nitrosylation (248)
24	Creatine kinase	S-Thionylation (55)
		Disulfide (32)
		Sulfenylation (46)
		S-Glutathionylation (31)
		S-Nitrosylation C ²⁵⁴ (38)
		Tyr-Nitration (187, 298)
25	Carnitine palmitoyl transferase 2	S-Nitrosylation (51)
26	Cytochrome C	Tyr-Nitration (44)
27	Cytochrome C oxidase	Sulfenylation (241)
		Hydroxylation W ³³⁴ (158)
		HNE (49)
		S-Nitrosylation (248)
		Sulfenylation
28	Cytosolic phospholipase A2	S-Nitrosylation (248)
29	Desmin	Sulfenylation (46, 241)
		S-Glutathionylation (31)
30	Dexamethasone-induced Ras-related protein 1	S-Nitrosylation (248)
31	Dihydropyrimidinase-related protein 2	S-Nitrosylation C ⁵⁰⁴ , C ²⁴⁸ (38)
32	Dihydrolipoyllysine-residue acetyltransferase	Sulfenylation (46)
33	Dynamin-1/2	S-Nitrosylation (248)
33	E3 ubiquitin-protein ligase	S-Nitrosylation (248)
34	E3 ubiquitin-protein ligase Mdm2	S-Nitrosylation (248)
35	Elongation factor 1-alpha	S-Nitrosylation (248)
36	Electron-transferring flavoprotein dehydrogenase	S-Nitrosylation (51)
37	Electron-transferring flavoprotein α polypeptide	S-Nitrosylation (51)
38	Enoyl-CoA hydratase	S-Nitrosylation (51)
39	eNOS	Glutathionylation C ⁶⁸⁹ , C ⁹⁰⁸ (48)
40	Fructose-bisphosphate aldolase A	Nitrosylation C ²⁰² (38)
41	Glucokinase	S-Nitrosylation (248)
42	Grx-1	S-Nitrosylation (248)

(continued)

TABLE 3. (CONTINUED)

<i>Serial no.</i>	<i>Name</i>	<i>Modification (site if known)</i>
43	Glutathione-S-transferase-Pi	HNE (293)
44	Glyceraldehyde 3 phosphate dehydrogenase	HNE C ²⁴⁵ (86, 130) S-Thionylation (68) S-Glutathionylation (31) Sulfonylation C ¹⁴⁹ (33) S-Nitrosylation C ¹⁴⁹ , C ²⁴⁵ (38, 86, 191, 250)
45	Hemoglobin	S-Nitrosylation (248)
46	Heat shock cognate 71 kDa protein	Nitrosylation C ⁶⁰³ , C ⁵⁷⁴ (38)
47	Heat-shock proteins	S-Thionylation (68) Disulfide (42) HNE (293)
48	Heat-shock protein 27	S-Thionylation (68)
49	Heat-shock protein 90-alpha	S-Nitrosylation (248)
48	Histone deacetylase 2	S-Nitrosylation (248)
49	H-Ras	Palmitoylation C ¹⁸¹ , C ¹⁸⁴ (114) Farnesylation C ¹⁸⁶ (114) S-Glutathionylation C ¹¹⁸ (3) S-Nitrosylation (248) S-Thionylation (68)
52	Human Growth Hormone-Releasing Factor	Methionine Sulfoxide (103)
53	Hypoxia-inducible factor 1-alpha	S-Nitrosylation (248)
54	Inhibitor of nuclear factor kappa-B kinase	S-Nitrosylation (248)
55	Insulin receptor	S-Nitrosylation (248)
56	Fe-responsive element-binding protein 2	S-Nitrosylation (248)
57	Isocitrate dehydrogenase	Disulfide C ³⁵¹ , C ³⁵⁹ (32, 86) Nitrosylation (51)
58	Lactate dehydrogenase	Sulfenylation (241) Nitrosylation C ¹⁶³ (38)
59	L-lactate dehydrogenase B chain	Nitrosylation C ¹⁶⁴ (38)
60	Long chain acyl-CoA dehydrogenase	S-Nitrosylation (51)
61	Low-density lipoprotein	KYN (205)
62	L-type Ca ²⁺ channel	S-Nitrosylation (40)
63	Malate dehydrogenase, cytosolic	Nitrosylation C ¹³⁷ , C ¹⁵⁴ (38, 84)
64	Malate dehydrogenase, mitochondrial	Sulfenylation (46, 241) S-Thionylation (68) Disulfide (32) S-Nitrosylation C ¹³⁷ (86)
65	MAP kinase 8	S-Nitrosylation (248)
66	Matrix metalloproteinase-9	S-Nitrosylation (248)
67	Microsomal glutathione S-transferase 1	S-Nitrosylation (248)
68	Muscle glycogen phosphorylase	Sulfenylation (46)
69	Myoglobin	S-Nitrosylation (273) S-Thionylation (68) Disulfide (32) Sulfenylation (241)
70	Myosin	Sulfenylation (241) S-Nitrosylation (51, 248) NFK W ⁷ , W ¹⁴ (70) KYN W ⁷ , W ¹⁴ (70) Disulfide (32)
71	Myosin heavy chain cardiac muscle α isoform	Sulfenylation (31, 46)
72	Myosin heavy chain cardiac β	Sulfenylation (46)
73	Myosin binding protein C	S-Glutathionylation (31)
74	NADH dehydrogenase	S-Nitrosylation (133) Disulfide (32)
75	Na ⁺ /K ⁺ ATPase	S-Thionylation (106)
76	Nucleoside diphosphate kinase B	S-Thionylation (68) Disulfide (32)
77	NF- κ B	S-Thionylation (43)
78	Nitric oxide synthase, endothelial	S-Nitrosylation (248)
79	NMDA receptor	S-Nitrosylation (248)
80	N-Ras	S-Nitrosylation (248)

(continued)

TABLE 3. (CONTINUED)

Serial no.	Name	Modification (site if known)
81	Nuclear factor NF-kappa-B p105 subunit	S-Nitrosylation (248)
82	Pgam1 protein	Nitrosylation (38)
83	Phosphoglycerate kinase 1	Nitrosylation C ⁵⁰ (38)
84	Phosphorylase-B kinase beta subunit	Glutathionylation C ⁸³⁸ (250, 251)
85	Protein kinase A	Disulfide (32)
86	Protein kinase C	S-Thionylation (68) Disulfide (32)
87	Protein-tyrosine phosphatase 1B	S-Thionylation (68) S-Nitrosylation (248)
88	Protein disulfide isomerase	S-Nitrosylation (248) HNE (293)
89	Pkm2 Isoform M1 of Pyruvate kinase isozymes M1/M2	Nitrosylation C ⁴⁹ , C ⁴²³ , C ⁴⁷⁴ (38)
90	Rab GDP dissociation inhibitor alpha	Nitrosylation C ³¹⁷ (38)
91	Ryanodine receptor	S-Nitrosylation C ^{36,35} (248, 314) S-Glutathionylation (215) S-Thionylation (122)
92	Sarco/endoplasmic reticulum Ca ²⁺ - ATPase	Tyr-Nitration Y ²⁹⁴ , Y ²⁹⁵ (304) S-Glutathionylation C ⁶⁶⁹ , C ⁶⁷⁴ (4, 215) S-Nitrosylation (248) Sulfonylation C ⁶⁷⁴ (4)
93	Short chain acyl-CoA dehydrogenase	Nitrosylation (51)
94	Stress-70 protein, mitochondrial	S-Nitrosylation (248) HNE (293)
95	Succinate dehydrogenase	S-Glutathionylation C ⁸⁹ (86) Nitrosylation (51) HNE (153) Disulfide (32)
96	SOD I [Cu-Zn]	NFK (70) KYN (70)
97	SOD II [Mn]	2-oxo histidine (136) Tyr-Nitration Y ³⁴ , Y ⁴⁵ , Y ¹⁹³ (174) Dityrosine (174)
98	Syntaxin-1A	S-Nitrosylation (248)
99	Thioredoxin-1	S-Nitrosylation (248)
100	Tissue-type plasminogen activator	S-Nitrosylation (248)
101	Tropomyosin	Sulfonylation (46, 241) Disulfide (32) Thionylation (42)
102	Troponin	Disulfide (32) Sulfonylation (241)
103	Troponin I, cardiac	Sulfonylation (46)
104	Troponin T, cardiac muscle	Sulfonylation (46)
105	Trifunctional enzyme α subunit	Sulfonylation (46) S-Glutathionylation (31)
106	Triosephosphate isomerase	S-Thionylation (68) Disulfide (32)
107	Tubulin alpha-1 chain	S-Nitrosylation C ³¹⁵ , C ³¹⁶ , C ³⁴⁷ , C ³⁷⁶ (38)
108	Tumor necrosis factor receptor superfamily	S-Nitrosylation (248)
109	Type-1 angiotensin II receptor	S-Nitrosylation (248)
110	Ubiquitin-conjugating enzyme E2 L3	S-Nitrosylation (248)
111	Very long chain acyl-CoA dehydrogenase	S-Nitrosylation (51)
112	Vesicle-fusing ATPase	S-Nitrosylation (248)
113	Voltage-gated potassium channel	S-Nitrosylation (248)

ADP, adenosine-5'-diphosphate; ATP, adenosine-5'-triphosphate; GDP, guanosine diphosphate; Glrx, glutaredoxin; HNE, 4-hydroxynonenal; KYN, kynurenine; NFK, N-formylkynurenine; SOD, superoxide dismutase.

may be reasonable modifications for studying biomarker identification.

Aromatic side chains of Phe, Tyr, and Trp can be easily oxidized and result in ring oxygenation; Trp can also undergo ring cleavage. Another ring structure, Oxo-histidine, is formed from metal-catalyzed oxidation of histidine (243), but

it is unclear whether this product is specific for radical chemistry. Trp forms oxidative by-product species that can also be enzymatically derived. Thus, His and Trp would be poor candidates for biomarkers. Phe can be modified by hydroxyl radicals to ortho- and meta-Tyr, which are stable and can be readily detectable by HPLC; these modifications have

been used to demonstrate the presence of oxidative stress in the plasma and urine (89, 208, 213). However, no human studies have been performed to evaluate specific proteins that undergo either changes in ortho-Tyr or meta-Tyr. Similarly, Tyr modification to chlorotyrosine, dityrosine, and 3-nitrotyrosine are specific for radical-induced modifications and would function well as oxidative biomarkers. The nitrotyrosine proteome has been evaluated in uremic patients and has identified fibrinogen chains, alpha-1 antitrypsin, transferrin, ceruloplasmin, and haptoglobin (216). For chlorotyrosine, atherosclerotic patients have been analyzed by Thomson, but no differences in the modifications were noted (279). Thus, particular focus on methionine sulfone, Cys sulfonic acid, and oxidative Tyr modifications for oxidative biomarker discovery should be considered, as these are stable, irreversible, nonenzymatic changes.

Although these studies were performed with plasma, the complex mixture of proteins in serum and the action of proteolytic enzymes activated during clotting may make it difficult to identify oxidatively modified serum proteins. Conversely, urine samples have far fewer components and can contain oxidatively modified peptides, indicating that they may also be used for analyzing excreted oxidative peptides (154, 155).

Traditional biomarkers of cardiac injury, troponin I and T can be detected in the plasma from patients with myocardial injury using sensitive immunoassays (287). Increased levels of three novel markers of subclinical myocardial injury (mid-regional pro-atrial natriuretic peptide, mid-regional pro-adrenomedullin, and C-terminal pro-endothelin-1) were independently associated with the risk of cardiovascular death or heart failure (237). While these biomarkers are quite useful in determining whether

a patient is in the midst of myocardial injury and an increased amount of protein has been released in response to cellular injury, the development of cardiovascular pathologies resulting from persistent elevations in oxidative damage may only be detected early by evaluating OPTMs.

A number of oxidant-sensitive proteins have been reported either during a pathological disease state or with direct oxidant treatment (Table 3), and among this group, several have the potential to be used as biomarkers. Creatine kinase and troponin I are already known cardiac biomarkers (29), but only the nitration of creatinine kinase would make it an ideal oxidative marker. The heart-specific myofibrillar proteins tropomyosin and actin could be candidates, as they have been shown to undergo disulfide cross-bridge formation during ischemia/reperfusion (42) and are carbonylated in human failing hearts (41). However, the modifications that these proteins undergo are enzymatically reversible, and, thus, the quantities can vary. The modulation of acyl-CoA dehydrogenase activity could indicate changes in the fatty acid oxidation status of failing hearts (167), and enzymes such as aspartate aminotransferase were observed to be indicative of diabetes and associated as risk factors for CVD (107), but both these undergo reversible modifications as well. On the other hand, aconitase 2, a Krebs cycle enzyme localized to the mitochondria, has been recognized as a potential biomarker (245), and its sulfonated modification should remain stable and measurable.

Conclusions

For more than a hundred years, the role of OPTMs has been studied. Antibody and MS analytics have been extensively used in the identification of OPTMs, and the functional significance of these modifications has been defined by the genetic modulation of reductive enzymes in animal models. A further discovery of the RNOS sources of several OPTMs will be needed to validate the importance of these modifications *in vivo*. In order to make further advances in the field, refinements in detection that allow for improved recognition of OPTMs, such as antibody recognition or better labeling techniques, will need to be developed.

The field of MS-based proteomics is constantly evolving and taking more sophisticated approaches to answer biological questions, yet it is still unable to resolve multiple modifications found in a complex proteome. In a typical MS analysis from a tissue extract or a cell lysate, there are many peptides that fail to be identified either due to their poor quality or because search algorithms are incapable of matching them to a known pattern. Recent developments in the field hold promise for improving on peptide identification. For instance, the new Q Executive instrument is a combination of a quadrupole mass filter with an Orbitrap analyzer and with its advanced configuration, has the capability to identify more than 2500 proteins in a single 90 min gradient from a mammalian cell lysate having undergone trypsin digestion (186). High-throughput instruments with both ESI and MALDI ionization capabilities have been advantageous because of their complementary nature (30). To better match mass peaks, error-tolerant searches with Mascot version 2.2 or later can perform analyses with semi-specific proteases, and can consider all the possible modifications and substitutions that can

arise from a single base substitution in the nucleic acid sequence. Although very helpful, these search parameters are limited foremost by our knowledge of variable modifications and technically by the number of variations that can be specified per search.

Currently, the cardiovascular evaluation of both the Redox and Ox stress proteomes are rarely delineated in the literature, and the terms are interchangeably used. Most fundamental evaluations have been done on the Redox sub-proteome of Cys (*S*-glutathionylation and *S*-nitrosylation) and the Ox stress sub-proteome of Tyr (nitration) and Lys/histidine (HNE). Each of these demonstrates importance as markers of CVD and appears to be pertinent for disease modification in myocardial infarction, hypertension, and inflammation. Further work, however, needs to be performed to determine the functional significance on other members of the redox proteome, such as methionine sulfide and carbonyls, both of which would be more likely to form under conditions of increased H₂O₂ production, a purported major mediator of cardiovascular phenotypes such as hypertension, cardiac hypertrophy, and heart failure (14). The role of the Ox stress proteome has mostly been evaluated on an associative basis (199). Animal models such as the aldehyde dehydrogenase, AR, and glutathione *S*-transferase transgenics and deletion mice may provide a better insight regarding the role of HNE in cardiovascular pathology. Lastly, screening for several of these Ox stress proteomes should be done in transgenic mice expressing catalase, mito-catalase, SOD, etc., to further delineate the roles of these OPTMs in disease states. Since analyses from MS can be incomplete, the creation of a specific OPTM database that collects and annotates published MS data would allow for future analysis when novel search methods are developed to aid in further discovery (147).

Acknowledgments

This work was supported by NIH grants PO1 HL 068758, R37 HL104017, R01 HL31607, and T32 HL007969 (TDC) as well as by NHLBI, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN268201000031C, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the awarding offices.

References

1. Achmann FL, Kwak GH, Del Conte R, Kim HY, Gladyshev VN, and Dikiy A. Structural and biochemical analysis of mammalian methionine sulfoxide reductase B2. *Proteins* 79: 3123–3131, 2011.
2. Abello N, Kerstjens HA, Postma DS, and Bischoff R. Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. *J Proteome Res* 8: 3222–3238, 2009.
3. Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, and Cohen RA. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 279: 29857–29862, 2004.
4. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schoneich C, and Cohen RA. S-Glutathiolation by perox-

- ynitrite activates SERCA during arterial relaxation by nitric oxide. *Nat Med* 10: 1200–1207, 2004.
5. Adluri RS, Thirunavukkarasu M, Zhan L, Akita Y, Samuel SM, Otani H, Ho YS, Maulik G, and Maulik N. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. *J Mol Cell Cardiol* 50: 239–247, 2011.
 6. Aebersold R and Mann M. Mass spectrometry-based proteomics. *Nature* 422: 198–207, 2003.
 7. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, and Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. *Cell* 133: 978–993, 2008.
 8. Ahmed ZM, Yousaf R, Lee BC, Khan SN, Lee S, Lee K, Husnain T, Rehman AU, Bonneux S, Ansar M, Ahmad W, Leal SM, Gladyshev VN, Belyantseva IA, Van Camp G, Riazuddin S, and Friedman TB. Functional null mutations of MSRB3 encoding methionine sulfoxide reductase are associated with human deafness DFNB74. *Am J Hum Genet* 88: 19–29, 2011.
 9. Allison WS. Formation and reactions of sulfenic acids in proteins. *Acc Chem Res* 9: 293–299, 1976.
 10. Amoresano A, Chiappetta G, Pucci P, D'Ischia M, and Marino G. Bidimensional tandem mass spectrometry for selective identification of nitration sites in proteins. *Anal Chem* 79: 2109–2117, 2007.
 11. Amoresano A, Monti G, Cirulli C, and Marino G. Selective detection and identification of phosphopeptides by dansyl MS/MS/MS fragmentation. *Rapid Commun Mass Spectrom* 20: 1400–1404, 2006.
 12. Arbault S, Pantano P, Sojic N, Amatore C, Best-Belpomme M, Sarasin A, and Vuillaume M. Activation of the NADPH oxidase in human fibroblasts by mechanical intrusion of a single cell with an ultramicroelectrode. *Carcinogenesis* 18: 569–574, 1997.
 13. Baba SP, Hellmann J, Srivastava S, and Bhatnagar A. Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). *Chem Biol Interact* 191: 357–363, 2011.
 14. Bachschmid MM, Schildknecht S, Matsui R, Zee R, Haeussler D, A Cohen R, Pimental D, and Loo BV. Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. *Ann Med* 2012 [Epub ahead of print]; DOI: 10.3109/07853890.2011.645498.
 15. Bachschmid MM, Xu S, Maitland-Toolan KA, Ho YS, Cohen RA, and Matsui R. Attenuated cardiovascular hypertrophy and oxidant generation in response to angiotensin II infusion in glutaredoxin-1 knockout mice. *Free Radic Biol Med* 49: 1221–1229, 2010.
 16. Backos DS, Fritz KS, Roede JR, Petersen DR, and Franklin CC. Posttranslational modification and regulation of glutamate-cysteine ligase by the α,β -unsaturated aldehyde 4-hydroxy-2-nonenal. *Free Radic Biol Med* 50: 14–26, 2011.
 17. Baran H, Staniek K, Kepplinger B, Stur J, Draxler M, and Nohl H. Kynurenines and the respiratory parameters on rat heart mitochondria. *Life Sci* 72: 1103–1115, 2003.
 18. Barreiro E and Hussain SN. Protein carbonylation in skeletal muscles: impact on function. *Antioxid Redox Signal* 12: 417–429, 2010.
 19. Baty JW, Hampton MB, and Winterbourn CC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis. *Proteomics* 2: 1261–1266, 2002.
 20. Bayer EA and Wilchek M. Application of avidin-biotin technology to affinity-based separations. *J Chromatogr* 510: 3–11, 1990.
 21. Beigi F, Gonzalez DR, Minhas KM, Sun QA, Foster MW, Khan SA, Treuer AV, Dulce RA, Harrison RW, Saraiva RM, Premer C, Schulman IH, Stamler JS, and Hare JM. Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. *Proc Natl Acad Sci U S A* 109: 4314–4319, 2012.
 22. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S, Nilsson T, and Bergeron JJ. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. *Nat Methods* 6: 423–430, 2009.
 23. Benedetti A, Comporti M, and Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. *Biochim Biophys Acta* 620: 281–296, 1980.
 24. Benhar M, Forrester MT, Hess DT, and Stamler JS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. *Science* 320: 1050–1054, 2008.
 25. Benhar M, Thompson JW, Moseley MA, and Stamler JS. Identification of S-nitrosylated targets of thioredoxin using a quantitative proteomic approach. *Biochemistry* 49: 6963–6969, 2010.
 26. Benitez LV and Allison WS. The inactivation of the acyl phosphatase activity catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate dehydrogenase by dimedone and olefins. *J Biol Chem* 249: 6234–6243, 1974.
 27. Berlett BS and Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem* 272: 20313–20316, 1997.
 28. Bhatnagar A. Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. *Circ Res* 76: 293–304, 1995.
 29. Bignami E, Landoni G, Crescenzi G, Gonfalini M, Bruno G, Pappalardo F, Marino G, Zangrillo A, and Alfieri O. Role of cardiac biomarkers (troponin I and CK-MB) as predictors of quality of life and long-term outcome after cardiac surgery. *Ann Card Anaesth* 12: 22–26, 2009.
 30. Bodnar WM, Blackburn RK, Krise JM, and Moseley MA. Exploiting the complementary nature of LC/MALDI/MS/MS and LC/ESI/MS/MS for increased proteome coverage. *J Am Soc Mass Spectrom* 14: 971–979, 2003.
 31. Brennan JP, Miller JI, Fuller W, Wait R, Begum S, Dunn MJ, and Eaton P. The utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. *Mol Cell Proteomics* MCP 5: 215–225, 2006.
 32. Brennan JP, Wait R, Begum S, Bell JR, Dunn MJ, and Eaton P. Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. *J Biol Chem* 279: 41352–41360, 2004.
 33. Britto PJ, Knipping L, and Wolff J. The local electrostatic environment determines cysteine reactivity of tubulin. *J Biol Chem* 277: 29018–29027, 2002.
 34. Brock JW, Cotham WC, Ames JM, Thorpe SR, and Baynes JW. Proteomic method for the quantification of methionine sulfoxide. *Ann N Y Acad Sci* 1043: 284–289, 2005.
 35. Brunk UT, Jones CB, and Sohal RS. A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions

- between oxidative stress and autophagocytosis. *Mutat Res* 275: 395–403, 1992.
36. Burgoyne JR, Haeussler DJ, Kumar V, Ji Y, Pimental DR, Zee RS, Costello CE, Lin C, McComb ME, Cohen RA, and Bachschmid MM. Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis. *FASEB J* 26: 832–841, 2012.
 37. Butterfield DA, Bader Lange ML, and Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. *Biochim Biophys Acta* 1801: 924–929, 2010.
 38. Camerini S, Polci ML, Restuccia U, Usueli V, Malgaroli A, and Bachi A. A novel approach to identify proteins modified by nitric oxide: the HIS-TAG switch method. *J Proteome Res* 6: 3224–3231, 2007.
 39. Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, and Winterbourn CC. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. *Hypertension* 47: 1155–1161, 2006.
 40. Campbell DL, Stamler JS, and Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. *J Gen Physiol* 108: 277–293, 1996.
 41. Canton M, Menazza S, Sheeran FL, Polverino de Laureto P, Di Lisa F, and Pepe S. Oxidation of myofibrillar proteins in human heart failure. *J Am Coll Cardiol* 57: 300–309, 2011.
 42. Canton M, Neverova I, Menabo R, Van Eyk J, and Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. *Am J Physiol Heart Circ Physiol* 286: H870–H877, 2004.
 43. Cargnoni A, Ceconi C, Gaia G, Agnoletti L, and Ferrari R. Cellular thiols redox status: a switch for NF-kappaB activation during myocardial post-ischaemic reperfusion. *J Mol Cell Cardiol* 34: 997–1005, 2002.
 44. Cassina AM, Hodara R, Souza JM, Thomson L, Castro L, Ischiropoulos H, Freeman BA, and Radi R. Cytochrome c nitration by peroxynitrite. *J Biol Chem* 275: 21409–21415, 2000.
 45. Chang YC, Huang CN, Lin CH, Chang HC, and Wu CC. Mapping protein cysteine sulfonic acid modifications with specific enrichment and mass spectrometry: an integrated approach to explore the cysteine oxidation. *Proteomics* 10: 2961–2971, 2010.
 46. Charles RL, Schroder E, May G, Free P, Gaffney PR, Wait R, Begum S, Heads RJ, and Eaton P. Protein sulfenation as a redox sensor: proteomics studies using a novel biotinylated dimesone analogue. *Mol Cell Proteomics: MCP* 6: 1473–1484, 2007.
 47. Chavez J, Wu J, Han B, Chung W-G, and Maier CS. New role for an old probe: affinity labeling of oxylipid protein conjugates by N'-aminooxymethylcarbonylhydrazino d-biotin. *Anal Chem* 78: 6847–6854, 2006.
 48. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, and Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. *Nature* 468: 1115–1118, 2010.
 49. Chen J, Henderson GI, and Freeman GL. Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused rat heart. *J Mol Cell Cardiol* 33: 1919–1927, 2001.
 50. Choi H, Tostes RC, and Webb RC. Thioredoxin reductase inhibition reduces relaxation by increasing oxidative stress and S-nitrosylation in mouse aorta. *J Cardiovasc Pharmacol* 58: 522–527, 2011.
 51. Chouchani ET, Hurd TR, Nadtochiy SM, Brookes PS, Fearnley IM, Lilley KS, Smith RA, and Murphy MP. Identification of S-nitrosated mitochondrial proteins by S-nitrosothiol difference in gel electrophoresis (SNO-DIGE): implications for the regulation of mitochondrial function by reversible S-nitrosation. *Biochem J* 430: 49–59, 2010.
 52. Chung KK, Dawson VL, and Dawson TM. S-nitrosylation in Parkinson's disease and related neurodegenerative disorders. *Methods Enzymol* 396: 139–150, 2005.
 53. Clavreul N, Adachi T, Pimental DR, Ido Y, Schoneich C, and Cohen RA. S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. *FASEB J* 20: 518–520, 2006.
 54. Codreanu SG, Zhang B, Sobocki SM, Billheimer DD, and Liebler DC. Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal. *Mol Cell Proteomics* 8: 670–680, 2009.
 55. Collison MW and Thomas JA. S-thiolation of cytoplasmic cardiac creatine kinase in heart cells treated with diamide. *Biochim Biophys Acta* 928: 121–129, 1987.
 56. Coombs KM. Quantitative proteomics of complex mixtures. *Expert Rev Proteomics* 8: 659–677, 2011.
 57. Cravatt BF, Simon GM, and Yates JR, 3rd. The biological impact of mass-spectrometry-based proteomics. *Nature* 450: 991–1000, 2007.
 58. Dakin HD. The oxidation of amino-acids with the production of substances of biological importance. *J Biol Chem* 1: 171–176, 1905.
 59. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, and Milzani A. Protein carbonylation in human diseases. *Trends Mol Med* 9: 169–176, 2003.
 60. Davies KJ. Protein damage and degradation by oxygen radicals. I. general aspects. *J Biol Chem* 262: 9895–9901, 1987.
 61. Dayon L, Hainard A, Licker V, Turck N, Kuhn K, Hochstrasser DF, Burkhard PR, and Sanchez JC. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. *Anal Chem* 80: 2921–2931, 2008.
 62. DeGray JA, Gunther MR, Tschirret-Guth R, Ortiz de Montellano PR, and Mason RP. Peroxidation of a specific tryptophan of metmyoglobin by hydrogen peroxide. *J Biol Chem* 272: 2359–2362, 1997.
 63. DiMarco T and Giulivi C. Current analytical methods for the detection of dityrosine, a biomarker of oxidative stress, in biological samples. *Mass Spectrom Rev* 26: 108–120, 2007.
 64. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, and Dyck JR. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. *Circulation* 119: 1643–1652, 2009.
 65. Domon B and Aebersold R. Mass spectrometry and protein analysis. *Science* 312: 212–217, 2006.
 66. Doulias PT, Greene JL, Greco TM, Tenopoulou M, Seeholzer SH, Dunbrack RL, and Ischiropoulos H. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. *Proc Natl Acad Sci U S A* 107: 16958–16963, 2010.
 67. Eaton P. Protein thiol oxidation in health and disease: techniques for measuring disulfides and related modifica-

- tions in complex protein mixtures. *Free Radic Biol Med* 40: 1889–1899, 2006.
68. Eaton P, Byers HL, Leeds N, Ward MA, and Shattock MJ. Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. *J Biol Chem* 277: 9806–9811, 2002.
69. Eaton P, Li JM, Hearse DJ, and Shattock MJ. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. *Am J Physiol* 276: H935–H943, 1999.
70. Ehrenshaft M, Silva SO, Perdivara I, Bilski P, Sik RH, Chignell CF, Tomer KB, and Mason RP. Immunological detection of N-formylkynurenine in oxidized proteins. *Free Radic Biol Med* 46: 1260–1266, 2009.
71. Eiserich JP, Patel RP, and O'Donnell VB. Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. *Mol Aspects Med* 19: 221–357, 1998.
72. Ellis HR and Poole LB. Novel application of 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole to identify cysteine sulfenic acid in the AhpC component of alkyl hydroperoxide reductase. *Biochemistry* 36: 15013–15018, 1997.
73. Endo J, Sano M, Katayama T, Hishiki T, Shinmura K, Morizane S, Matsuhashi T, Katsumata Y, Zhang Y, Ito H, Nagahata Y, Marchitti S, Nishimaki K, Wolf AM, Nakanishi H, Hattori F, Vasiliou V, Adachi T, Ohsawa I, Taguchi R, Hirabayashi Y, Ohta S, Suematsu M, Ogawa S, and Fukuda K. Metabolic remodeling induced by mitochondrial aldehyde stress stimulates tolerance to oxidative stress in the heart. *Circ Res* 105: 1118–1127, 2009.
74. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, and Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. *Cell* 133: 462–474, 2008.
75. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 11: 81–128, 1991.
76. Fan X, Zhang J, Theves M, Strauch C, Nemet I, Liu X, Qian J, Giblin FJ, and Monnier VM. Mechanism of lysine oxidation in human lens crystallins during aging and in diabetes. *J Biol Chem* 284: 34618–34627, 2009.
77. Faraggi M, DeFelippis MR, and Klapper MH. Long-range electron transfer between tyrosine and tryptophan in peptides. *J Am Chem Soc* 111: 5141–5145, 1989.
78. Fedorova M, Todorovsky T, Kuleva N, and Hoffmann R. Quantitative evaluation of tryptophan oxidation in actin and troponin I from skeletal muscles using a rat model of acute oxidative stress. *Proteomics* 10: 2692–2700, 2010.
79. Fenaille F, Tabet J-C, and Guy PA. Immunoaffinity purification and characterization of 4-hydroxy-2-nonenal- and malondialdehyde-modified peptides by electrospray ionization tandem mass spectrometry. *Anal Chem* 74: 6298–6304, 2002.
80. Fomenko DE, Marino SM, and Gladyshev VN. Functional diversity of cysteine residues in proteins and unique features of catalytic redox-active cysteines in thiol oxidoreductases. *Mol Cells* 26: 228–235, 2008.
81. Fomenko DE, Novoselov SV, Natarajan SK, Lee BC, Koc A, Carlson BA, Lee TH, Kim HY, Hatfield DL, and Gladyshev VN. MsrB1 (methionine-R-sulfoxide reductase 1) knock-out mice: roles of MsrB1 in redox regulation and identification of a novel selenoprotein form. *J Biol Chem* 284: 5986–5993, 2009.
82. Fomenko DE, Xing W, Adair BM, Thomas DJ, and Gladyshev VN. High-throughput identification of catalytic redox-active cysteine residues. *Science* 315: 387–389, 2007.
83. Forrester MT, Foster MW, Benhar M, and Stamler JS. Detection of protein S-nitrosylation with the biotin-switch technique. *Free Radic Biol Med* 46: 119–126, 2009.
84. Forrester MT, Thompson JW, Foster MW, Nogueira L, Moseley MA, and Stamler JS. Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture. *Nat Biotechnol* 27: 557–559, 2009.
85. Fritz KS, Kellersberger KA, Gomez JD, and Petersen DR. 4-HNE Adduct stability characterized by collision-induced dissociation and electron transfer dissociation mass spectrometry. *Chem Res Toxicol* 25: 965–970, 2012.
86. Fu C, Hu J, Liu T, Ago T, Sadoshima J, and Li H. Quantitative analysis of redox-sensitive proteome with DIGE and ICAT. *J Proteome Res* 7: 3789–3802, 2008.
87. Fu C, Wu C, Liu T, Ago T, Zhai P, Sadoshima J, and Li H. Elucidation of thioredoxin target protein networks in mouse. *Mol Cell Proteomics* 8: 1674–1687, 2009.
88. Gallogly MM and Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. *Curr Opin Pharmacol* 7: 381–391, 2007.
89. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, and Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. *Hypertension* 36: 430–435, 2000.
90. Garrison WM. Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins. *Chem Rev* 87: 381–398, 1987.
91. Ghesquiere B, Jonckheere V, Colaert N, Van Durme J, Timmerman E, Goethals M, Schymkowitz J, Rousseau F, Vandekerckhove J, and Gevaert K. Redox proteomics of protein-bound methionine oxidation. *Mol Cell Proteomics* 10: M110 006866, 2011.
92. Gieseg SP, Simpson JA, Charlton TS, Duncan MW, and Dean RT. Protein-bound 3,4-dihydroxyphenylalanine is a major reductant formed during hydroxyl radical damage to proteins. *Biochemistry* 32: 4780–4786, 1993.
93. Gil P, Farinas F, Casado A, and Lopez-Fernandez E. Malondialdehyde: a possible marker of ageing. *Gerontology* 48: 209–214, 2002.
94. Giorgio M, Trinei M, Migliaccio E, and Pelicci PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? *Nat Rev Mol Cell Biol* 8: 722–728, 2007.
95. Gitler C, Zarmi B, and Kalef E. General method to identify and enrich vicinal thiol proteins present in intact cells in the oxidized, disulfide state. *Anal Biochem* 252: 48–55, 1997.
96. Giulivi C, Traaseth NJ, and Davies KJ. Tyrosine oxidation products: analysis and biological relevance. *Amino acids* 25: 227–232, 2003.
97. Go YM, Pohl J, and Jones DP. Quantification of redox conditions in the nucleus. *Methods Mol Biol* 464: 303–317, 2009.
98. Grandhee SK and Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. *J Biol Chem* 266: 11649–11653, 1991.

99. Grimaud R, Ezraty B, Mitchell JK, Lafitte D, Briand C, Derrick PJ, and Barras F. Repair of oxidized proteins. Identification of a new methionine sulfoxide reductase. *J Biol Chem* 276: 48915–48920, 2001.
100. Grimsrud PA, Picklo MJ, Sr., Griffin TJ, and Bernlohr DA. Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. *Mol Cell Proteomics* 6: 624–637, 2007.
101. Grune T, Jung T, Merker K, and Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. *Int J Biochem Cell Biol* 36: 2519–2530, 2004.
102. Grunert T, Pock K, Buchacher A, and Allmaier G. Selective solid-phase isolation of methionine-containing peptides and subsequent matrix-assisted laser desorption/ionization mass spectrometric detection of methionine- and of methionine-sulfoxide-containing peptides. *Rapid Commun Mass Spectrom* 17: 1815–1824, 2003.
103. Guan Z, Yates NA, and Bakhtiar R. Detection and characterization of methionine oxidation in peptides by collision-induced dissociation and electron capture dissociation. *J Am Soc Mass Spectrom* 14: 605–613, 2003.
104. Guptasarma P and Balasubramanian D. Dityrosine formation in the proteins of the eye lens. *Curr Eye Res* 11: 1121–1125, 1992.
105. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, and Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. *Nat Biotechnol* 17: 994–999, 1999.
106. Haddock PS, Shattock MJ, and Hearse DJ. Modulation of cardiac Na(+)-K+ pump current: role of protein and non-protein sulfhydryl redox status. *Am J Physiol* 269: H297–H307, 1995.
107. Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. *Obesity* 14 Suppl 3: 121S–127S, 2006.
108. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, and Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. *J Mol Cell Cardiol* 42: 884–895, 2007.
109. Hampton MB, Kettle AJ, and Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. *Blood* 92: 3007–3017, 1998.
110. Han B, Stevens JF, and Maier CS. Design, synthesis, and application of a hydrazide-functionalized isotope-coded affinity tag for the quantification of oxylipid-protein conjugates. *Anal Chem* 79: 3342–3354, 2007.
111. Han D, Canali R, Garcia J, Aguilera R, Gallaher TK, and Cadenas E. Sites and mechanisms of aconitase inactivation by peroxynitrite: modulation by citrate and glutathione. *Biochemistry* 44: 11986–11996, 2005.
112. Han D, Canali R, Rettori D, and Kaplowitz N. Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. *Mol Pharmacol* 64: 1136–1144, 2003.
113. Hanbauer I and Moskovitz J. The yeast cytosolic thiorodoxins are involved in the regulation of methionine sulfoxide reductase A. *Free Radic Biol Med* 40: 1391–1396, 2006.
114. Hancock JF. Ras proteins: different signals from different locations. *Nat Rev Mol Cell Biol* 4: 373–384, 2003.
115. Hanson SR, Chen AA, Smith JB, and Lou MF. Thiolation of the gammaB-crystallins in intact bovine lens exposed to hydrogen peroxide. *J Biol Chem* 274: 4735–4742, 1999.
116. Hao G, Derakhshan B, Shi L, Campagne F, and Gross SS. SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. *Proc Natl Acad Sci U S A* 103: 1012–1017, 2006.
117. Hawkins CL, Morgan PE, and Davies MJ. Quantification of protein modification by oxidants. *Free Radic Biol Med* 46: 965–988, 2009.
118. Headlam HA and Davies MJ. Beta-scission of side-chain alkoxy radicals on peptides and proteins results in the loss of side-chains as aldehydes and ketones. *Free Radic Biol Med* 32: 1171–1184, 2002.
119. Headlam HA, Mortimer A, Easton CJ, and Davies MJ. beta-Scission of C-3 (beta-carbon) alkoxy radicals on peptides and proteins: a novel pathway which results in the formation of alpha-carbon radicals and the loss of amino acid side chains. *Chem Res Toxicol* 13: 1087–1095, 2000.
120. Heeba G, Moselhy ME, Hassan M, Khalifa M, Gryglewski R, and Malinski T. Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. *Br J Pharmacol* 156: 1256–1266, 2009.
121. Hensley K. Detection of protein carbonyls by means of biotin hydrazide-streptavidin affinity methods. *Methods Mol Biol* 536: 457–462, 2009.
122. Hidalgo C, Aracena P, Sanchez G, and Donoso P. Redox regulation of calcium release in skeletal and cardiac muscle. *Biol Res* 35: 183–193, 2002.
123. Hill BG, Dranka BP, Zou L, Chatham JC, and Darley-Usmar VM. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. *Biochem J* 424: 99–107, 2009.
124. Ho YS, Xiong Y, Ho DS, Gao J, Chua BH, Pai H, and Mieyal JJ. Targeted disruption of the glutaredoxin 1 gene does not sensitize adult mice to tissue injury induced by ischemia/reperfusion and hyperoxia. *Free Radic Biol Med* 43: 1299–1312, 2007.
125. Hoffmann FW, Hashimoto AS, Lee BC, Rose AH, Shohet RV, and Hoffmann PR. Specific antioxidant selenoproteins are induced in the heart during hypertrophy. *Arch Biochem Biophys* 512: 38–44, 2011.
126. Hollemeyer K, Heinzle E, and Tholey A. Identification of oxidized methionine residues in peptides containing two methionine residues by derivatization and matrix-assisted laser desorption/ionization mass spectrometry. *Proteomics* 2: 1524–1531, 2002.
127. Hu W, Tedesco S, Faedda R, Petrone G, Cacciola SO, O'Keefe A, and Sheehan D. Covalent selection of the thiol proteome on activated thiol sepharose: a robust tool for redox proteomics. *Talanta* 80: 1569–1575, 2010.
128. Imlay JA. Pathways of oxidative damage. *Annu Rev Microbiol* 57: 395–418, 2003.
129. Irie Y, Saeki M, Kamisaki Y, Martin E, and Murad F. Histone H1.2 is a substrate for denitrase, an activity that reduces nitrotyrosine immunoreactivity in proteins. *Proc Natl Acad Sci U S A* 100: 5634–5639, 2003.
130. Ishii T, Tatsuda E, Kumazawa S, Nakayama T, and Uchida K. Molecular basis of enzyme inactivation by an endogenous electrophile 4-hydroxy-2-nonenal: identification of modification sites in glyceraldehyde-3-phosphate dehydrogenase. *Biochemistry* 42: 3474–3480, 2003.

131. Jaffrey SR and Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. *Sci STKE* 2001: pl1, 2001.
132. Jagannadham MV. Identifying the sequence and distinguishing the oxidized—methionine from phenylalanine peptides by MALDI TOF/TOF mass spectrometry in an antarctic bacterium *Pseudomonas syringae*. *Proteomics Insights* 2: 27, 2009.
133. Jekabsone A, Ivanoviene L, Brown GC, and Borutaite V. Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release. *J Mol Cell Cardiol* 35: 803–809, 2003.
134. Ji B, Ito K, Suzuki H, Sugiyama Y, and Horie T. Multi-drug resistance-associated protein2 (MRP2) plays an important role in the biliary excretion of glutathione conjugates of 4-hydroxynonenal. *Free Radic Biol Med* 33: 370–378, 2002.
135. Jiang T, Zhou X, Taghizadeh K, Dong M, and Dedon PC. N-formylation of lysine in histone proteins as a secondary modification arising from oxidative DNA damage. *Proc Natl Acad Sci U S A* 104: 60–65, 2007.
136. John JP, Pollak A, and Lubec G. Complete sequencing and oxidative modification of manganese superoxide dismutase in medulloblastoma cells. *Electrophoresis* 30: 3006–3016, 2009.
137. Judge S, Jang YM, Smith A, Selman C, Phillips T, Speakman JR, Hagen T, and Leeuwenburgh C. Exercise by lifelong voluntary wheel running reduces subsarcolemmal and interfibrillar mitochondrial hydrogen peroxide production in the heart. *Am J Physiol Regul Integr Comp Physiol* 289: R1564–R1572, 2005.
138. Kamisaki Y, Wada K, Bian K, Balabanli B, Davis K, Martin E, Behbod F, Lee YC, and Murad F. An activity in rat tissues that modifies nitrotyrosine-containing proteins. *Proc Natl Acad Sci U S A* 95: 11584–11589, 1998.
139. Kanski J, Alterman MA, and Schoneich C. Proteomic identification of age-dependent protein nitration in rat skeletal muscle. *Free Radic Biol Med* 35: 1229–1239, 2003.
140. Kanski J, Behring A, Pelling J, and Schoneich C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. *Am J Physiol Heart Circ Physiol* 288: H371–H381, 2005.
141. Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain JR, Jin LL, Harris IS, Mori J, Mak TW, Senis YA, Ostman A, Moran MF, and Neel BG. Global proteomic assessment of the classical protein-tyrosine phosphatome and “Redoxome”. *Cell* 146: 826–840, 2011.
142. Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, Takita T, Furuhashi M, Maruyama Y, Chida K, and Hishida A. Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. *Hemodial Int* 14: 418–424, 2010.
143. Kim HY and Gladyshev VN. Methionine sulfoxide reduction in mammals: characterization of methionine-R-sulfoxide reductases. *Mol Biol Cell* 15: 1055–1064, 2004.
144. Kim HY and Kim JR. Thioredoxin as a reducing agent for mammalian methionine sulfoxide reductases B lacking resolving cysteine. *Biochem Biophys Res Commun* 371: 490–494, 2008.
145. Kimura H, Liu S, Yamada S, Uchida K, Matsumoto K, Mukaida M, and Yoshida K. Rapid increase in serum lipid peroxide 4-hydroxynonenal (HNE) through monocyte NADPH oxidase in early endo-toxemia. *Free Radic Res* 39: 845–851, 2005.
146. King M, Gildemeister O, Gaston B, and Mannick JB. Assessment of S-nitrosothiols on diamino fluorescein gels. *Anal Biochem* 346: 69–76, 2005.
147. Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, Bradshaw R, Brusniak MY, Chan DW, Deutsch EW, Domon B, Gorman J, Grimm R, Hancock W, Hermjakob H, Horn D, Hunter C, Kolar P, Kraus HJ, Langen H, Linding R, Moritz RL, Omenn GS, Orlando R, Pandey A, Ping P, Rahbar A, Rivers R, Seymour SL, Simpson RJ, Slotta D, Smith RD, Stein SE, Tabb DL, Tagle D, Yates JR, and Rodriguez H. Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles). *Proteomics* 12: 11–20, 2012.
148. Kinumi T, Shimomae Y, Arakawa R, Tatsu Y, Shigeri Y, Yumoto N, and Niki E. Effective detection of peptides containing cysteine sulfonic acid using matrix-assisted laser desorption/ionization and laser desorption/ionization on porous silicon mass spectrometry. *J Mass Spectrom: JMS* 41: 103–112, 2006.
149. Klomsiri C, Nelson KJ, Bechtold E, Soito L, Johnson LC, Lowther WT, Ryu SE, King SB, Furdul CM, and Poole LB. Use of dimedone-based chemical probes for sulfenic acid detection evaluation of conditions affecting probe incorporation into redox-sensitive proteins. *Methods Enzymol* 473: 77–94, 2010.
150. Kumar V, Kitaef N, Hampton MB, Cannell MB, and Winterbourn CC. Reversible oxidation of mitochondrial peroxiredoxin 3 in mouse heart subjected to ischemia and reperfusion. *FEBS Lett* 583: 997–1000, 2009.
151. Landar A, Zmijewski JW, Dickinson DA, Le Goffe C, Johnson MS, Milne GL, Zanoni G, Vidari G, Morrow JD, and Darley-Usmar VM. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. *Am J Physiol Heart Circ Physiol* 290: H1777–H1787, 2006.
152. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science* 295: 858–861, 2002.
153. Lashin OM, Szweda PA, Szweda LI, and Romani AM. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. *Free Radic Biol Med* 40: 886–896, 2006.
154. Leeuwenburgh C, Hansen PA, Holloszy JO, and Heinecke JW. Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary di-tyrosine. *Free Radic Biol Med* 27: 186–192, 1999.
155. Leeuwenburgh C, Hansen PA, Holloszy JO, and Heinecke JW. Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. *Am J Physiol* 276: R128–R135, 1999.
156. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, and Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. *J Biol Chem* 272: 3520–3526, 1997.
157. Leichert LI, Gehrke F, Gudiseva HV, Blackwell T, Ilbert M, Walker AK, Strahler JR, Andrews PC, and Jakob U. Quantifying changes in the thiol redox proteome upon oxidative stress in vivo. *Proc Natl Acad Sci U S A* 105: 8197–8202, 2008.
158. Lemma-Gray P, Weintraub ST, Carroll CA, Musatov A, and Robinson NC. Tryptophan 334 oxidation in bovine

- cytochrome c oxidase subunit I involves free radical migration. *FEBS Lett* 581: 437–442, 2007.
159. Lenz AG, Costabel U, Shaltiel S, and Levine RL. Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium borohydride. *Anal Biochem* 177: 419–425, 1989.
 160. Leonard SE, Reddie KG, and Carroll KS. Mining the thiol proteome for sulfenic acid modifications reveals new targets for oxidation in cells. *ACS Chem Biol* 4: 783–799, 2009.
 161. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, and Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. *Methods Enzymol* 186: 464–478, 1990.
 162. Levine RL, Mosoni L, Berlett BS, and Stadtman ER. Methionine residues as endogenous antioxidants in proteins. *Proc Natl Acad Sci U S A* 93: 15036–15040, 1996.
 163. Lillig CH and Holmgren A. Thioredoxin and related molecules—from biology to health and disease. *Antioxid Redox Signal* 9: 25–47, 2007.
 164. Lim JC, You Z, Kim G, and Levine RL. Methionine sulfide reductase A is a stereospecific methionine oxidase. *Proc Natl Acad Sci U S A* 108: 10472–10477, 2011.
 165. Lim KH, Ancrile BB, Kashatus DF, and Counter CM. Tumour maintenance is mediated by eNOS. *Nature* 452: 646–649, 2008.
 166. Lima B, Lam GK, Xie L, Diesen DL, Villamizar N, Nienaber J, Messina E, Bowles D, Kontos CD, Hare JM, Stamler JS, and Rockman HA. Endogenous S-nitrosothiols protect against myocardial injury. *Proc Natl Acad Sci U S A* 106: 6297–6302, 2009.
 167. Lionetti V, Stanley WC, and Recchia FA. Modulating fatty acid oxidation in heart failure. *Cardiovasc Res* 90: 202–209, 2011.
 168. Liu L, Hausladen A, Zeng M, Que L, Heitman J, and Stamler JS. A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. *Nature* 410: 490–494, 2001.
 169. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, McMahon TJ, Dickfeld T, Marshall HE, Que LG, and Stamler JS. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. *Cell* 116: 617–628, 2004.
 170. Liu X, Shan B, Xin L, and Ma B. Better score function for peptide identification with ETD MS/MS spectra. *BMC Bioinform* 11 Suppl 1: S4, 2010.
 171. Lubec G and Afjehi-Sadat L. Limitations and pitfalls in protein identification by mass spectrometry. *Chem Rev* 107: 3568–3584, 2007.
 172. Luo J, Hill BG, Gu Y, Cai J, Srivastava S, Bhatnagar A, and Prabhu SD. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. *Am J Physiol Heart Circ Physiol* 293: H3673–H3684, 2007.
 173. Luo S and Levine RL. Methionine in proteins defends against oxidative stress. *FASEB J* 23: 464–472, 2009.
 174. MacMillan-Crow LA, Crow JP, and Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. *Biochemistry* 37: 1613–1622, 1998.
 175. Macmillan-Crow LA and Cruthirds DL. Invited review: manganese superoxide dismutase in disease. *Free Radic Res* 34: 325–336, 2001.
 176. Madian AG and Regnier FE. Proteomic identification of carbonylated proteins and their oxidation sites. *J Proteome Res* 9: 3766–3780, 2010.
 177. Maisonneuve E, Frayssé L, Lignon S, Capron L, and Dukan S. Carbonylated proteins are detectable only in a degradation-resistant aggregate state in *Escherichia coli*. *J Bacteriol* 190: 6609–6614, 2008.
 178. Malinouski M, Zhou Y, Belousov VV, Hatfield DL, and Gladyshev VN. Hydrogen peroxide probes directed to different cellular compartments. *PLoS One* 6: e14564, 2011.
 179. Manini P, Andreoli R, Sforza S, Dall'Asta C, Galaverna G, Mutti A, and Niessen WM. Evaluation of alternate isotope-coded derivatization assay (AIDA) in the LC-MS/MS analysis of aldehydes in exhaled breath condensate. *J Chromatogr B Analyt Technol Biomed Life Sci* 878: 2616–2622, 2010.
 180. Marzabadi MR, Yin D, and Brunk UT. Lipofuscinogenesis in a model system of cultured cardiac myocytes. *EXS* 62: 78–88, 1992.
 181. Maskos Z, Rush JD, and Koppenol WH. The hydroxylation of tryptophan. *Arch Biochem Biophys* 296: 514–520, 1992.
 182. McCord JM and Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). *J Biol Chem* 244: 6049–6055, 1969.
 183. McCord JM, Keele BB, Jr., and Fridovich I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. *Proc Natl Acad Sci U S A* 68: 1024–1027, 1971.
 184. Meagher EA, Barry OP, Lawson JA, Rokach J, and Fitzgerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. *JAMA* 285: 1178–1182, 2001.
 185. Meany DL, Xie H, Thompson LV, Arriaga EA, and Griffin TJ. Identification of carbonylated proteins from enriched rat skeletal muscle mitochondria using affinity chromatography-stable isotope labeling and tandem mass spectrometry. *Proteomics* 7: 1150–1163, 2007.
 186. Michalski A, Damoc E, Hauschild JP, Lange O, Wiegand A, Makarov A, Nagaraj N, Cox J, Mann M, and Horning S. Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. *Mol Cell Proteomics* 10: M111 011015, 2011.
 187. Mihm MJ and Bauer JA. Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase. *Biochimie* 84: 1013–1019, 2002.
 188. Mirzaei H and Regnier F. Affinity chromatographic selection of carbonylated proteins followed by identification of oxidation sites using tandem mass spectrometry. *Anal Chem* 77: 2386–2392, 2005.
 189. Miyata T, Kurokawa K, and van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. *Kidney Int Suppl* 76: S120–S125, 2000.
 190. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, and Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. *J Am Coll Cardiol* 49: 1993–2000, 2007.
 191. Mohr S, Stamler JS, and Brune B. Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. *J Biol Chem* 271: 4209–4214, 1996.
 192. Molina H, Horn DM, Tang N, Mathivanan S, and Pandey A. Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. *Proc Natl Acad Sci U S A* 104: 2199–2204, 2007.
 193. Montine KS, Olson SJ, Amarnath V, Whetsell WO, Jr., Graham DG, and Montine TJ. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's

- disease is associated with inheritance of APOE4. *Am J Pathol* 150: 437–443, 1997.
194. Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, and Stadtman ER. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. *Proc Natl Acad Sci U S A* 98: 12920–12925, 2001.
195. Moskovitz J and Oien DB. Protein carbonyl and the methionine sulfoxide reductase system. *Antioxid Redox Signal* 12: 405–415, 2010.
196. Moskovitz J, Singh VK, Requena J, Wilkinson BJ, Jayaswal RK, and Stadtman ER. Purification and characterization of methionine sulfoxide reductases from mouse and *Staphylococcus aureus* and their substrate stereospecificity. *Biochem Biophys Res Commun* 290: 62–65, 2002.
197. Moskovitz J, Weissbach H, and Brot N. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. *Proc Natl Acad Sci U S A* 93: 2095–2099, 1996.
198. Murray CI, Uhrigshardt H, O'Meally RN, Cole RN, and Van Eyk JE. Identification and quantification of S-nitrosylation by cysteine reactive tandem mass tag switch assay. *Mol Cell Proteomics* 11: M111 013441, 2012.
199. Nagy P, Kettle AJ, and Winterbourn CC. Superoxide-mediated formation of tyrosine hydroperoxides and methionine sulfoxide in peptides through radical addition and intramolecular oxygen transfer. *J Biol Chem* 284: 14723–14733, 2009.
200. Nakamura K, Miura D, Kusano KF, Fujimoto Y, Sumita-Yoshikawa W, Fuke S, Nishii N, Nagase S, Hata Y, Morita H, Matsubara H, Ohe T, and Ito H. 4-Hydroxy-2-nonenal induces calcium overload via the generation of reactive oxygen species in isolated rat cardiac myocytes. *J Card Fail* 15: 709–716, 2009.
201. Nan C, Li Y, Jean-Charles PY, Chen G, Kreymerman A, Prentice H, Weissbach H, and Huang X. Deficiency of methionine sulfoxide reductase A causes cellular dysfunction and mitochondrial damage in cardiac myocytes under physical and oxidative stresses. *Biochem Biophys Res Commun* 402: 608–613, 2010.
202. Nauser T and Schoneich C. Thiyl radicals abstract hydrogen atoms from the (alpha)C-H bonds in model peptides: absolute rate constants and effect of amino acid structure. *J Am Chem Soc* 125: 2042–2043, 2003.
203. Netto LE, de Oliveira MA, Monteiro G, Demasi AP, Cussiol JR, Discola KF, Demasi M, Silva GM, Alves SV, Faria VG, and Horta BB. Reactive cysteine in proteins: protein folding, antioxidant defense, redox signaling and more. *Comp Biochem Physiol C Toxicol Pharmacol* 146: 180–193, 2007.
204. Nikov G, Bhat V, Wishnok JS, and Tannenbaum SR. Analysis of nitrated proteins by nitrotyrosine-specific affinity probes and mass spectrometry. *Anal Biochem* 320: 214–222, 2003.
205. Obama T, Kato R, Masuda Y, Takahashi K, Aiuchi T, and Itabe H. Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. *Proteomics* 7: 2132–2141, 2007.
206. Oien DB, Canello T, Gabizon R, Gasset M, Lundquist BL, Burns JM, and Moskovitz J. Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies. *Arch Biochem Biophys* 485: 35–40, 2009.
207. Orhan H, Coolen S, and Meerman JH. Quantification of urinary o,o'-dityrosine, a biomarker for oxidative damage to proteins, by high performance liquid chromatography with triple quadrupole tandem mass spectrometry. A comparison with ion-trap tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 827: 104–108, 2005.
208. Orhan H, Vermeulen NP, Tump C, Zappey H, and Meerman JH. Simultaneous determination of tyrosine, phenylalanine and deoxyguanosine oxidation products by liquid chromatography-tandem mass spectrometry as non-invasive biomarkers for oxidative damage. *J Chromatogr B Analyt Technol Biomed Life Sci* 799: 245–254, 2004.
209. Pamplona R. Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. *Biochim Biophys Acta* 1777: 1249–1262, 2008.
210. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, and Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. *Free Radic Biol Med* 27: 1080–1086, 1999.
211. Pawlak K, Domaniewski T, Mysliwiec M, and Pawlak D. The kynurenes are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. *Atherosclerosis* 204: 309–314, 2009.
212. Peluffo G and Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. *Cardiovasc Res* 75: 291–302, 2007.
213. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, and Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. *J Clin Invest* 107: 853–860, 2001.
214. Perdivara I, Deterding LJ, Przybylski M, and Tomer KB. Mass spectrometric identification of oxidative modifications of tryptophan residues in proteins: chemical artifact or post-translational modification? *J Am Soc Mass Spectrom* 21: 1114–1117, 2010.
215. Pimentel D, Haeussler DJ, Matsui R, Burgoyne J, Cohen RA, and Bachschmid M. Regulation of cell physiology and pathology by protein S-glutathionylation. Lessons learned from the cardiovascular system. *Antioxid Redox Signal* 16: 524–542, 2012.
216. Piroddi M, Palmese A, Pilolli F, Amoresano A, Pucci P, Ronco C, and Galli F. Plasma nitroproteome of kidney disease patients. *Amino acids* 40: 653–667, 2011.
217. Pocernich CB and Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. *Neurotox Res* 5: 515–520, 2003.
218. Poole LB, Klomsiri C, Knaggs SA, Furdul CM, Nelson KJ, Thomas MJ, Fetrow JS, Daniel LW, and King SB. Fluorescent and affinity-based tools to detect cysteine sulfenic acid formation in proteins. *Bioconjugate Chem* 18: 2004–2017, 2007.
219. Pratico D. In vivo measurement of the redox state. *Lipids* 36 Suppl: S45–S47, 2001.
220. Privat C, Stepien O, David-Dufilho M, Brunet A, Bedioui F, Marche P, Devynck J, and Devynck MA. Superoxide release from interleukin-1B-stimulated human vascular cells: in situ electrochemical measurement. *Free Radic Biol Med* 27: 554–559, 1999.
221. Prutz WA, Butler J, Land EJ, and Swallow AJ. The role of sulphur peptide functions in free radical transfer: a pulse radiolysis study. *Int J Radiat Biol* 55: 539–556, 1989.
222. Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, and Stamler JS. Protection from experimental asthma

- by an endogenous bronchodilator. *Science* 308: 1618–1621, 2005.
223. Radi R, Cassina A, Hodara R, Quijano C, and Castro L. Peroxynitrite reactions and formation in mitochondria. *Free Radic Biol Med* 33: 1451–1464, 2002.
 224. Ramsey JJ, Hagopian K, Kenny TM, Koomson EK, Bevilacqua L, Weindrich R, and Harper ME. Proton leak and hydrogen peroxide production in liver mitochondria from energy-restricted rats. *Am J Physiol Endocrinol Metab* 286: E31–E40, 2004.
 225. Rao PS and Mueller HS. Lipid peroxidation and acute myocardial ischemia. *Adv Exp Med Biol* 161: 347–363, 1983.
 226. Rauniyar N, Stevens SM, Jr., and Prokai L. Fourier transform ion cyclotron resonance mass spectrometry of covalent adducts of proteins and 4-hydroxy-2-nonenal, a reactive end-product of lipid peroxidation. *Anal Bioanal Chem* 389: 1421–1428, 2007.
 227. Rauniyar N, Stevens SM, Prokai-Tatrai K, and Prokai L. Characterization of 4-hydroxy-2-nonenal-modified peptides by liquid chromatography-tandem mass spectrometry using data-dependent acquisition: neutral loss-driven MS3 versus neutral loss-driven electron capture dissociation. *Anal Chem* 81: 782–789, 2009.
 228. Rehder DS and Borges CR. Possibilities and pitfalls in quantifying the extent of cysteine sulfenic acid modification of specific proteins within complex biofluids. *BMC Biochem* 11: 25, 2010.
 229. Reichard JF, Vasiliou V, and Petersen DR. Characterization of 4-hydroxy-2-nonenal metabolism in stellate cell lines derived from normal and cirrhotic rat liver. *Biochim Biophys Acta* 1487: 222–232, 2000.
 230. Reinders J, Lewandrowski U, Moebius J, Wagner Y, and Sickmann A. Challenges in mass spectrometry-based proteomics. *Proteomics* 4: 3686–3703, 2004.
 231. Requejo R, Hurd TR, Costa NJ, and Murphy MP. Cysteine residues exposed on protein surfaces are the dominant intramitochondrial thiol and may protect against oxidative damage. *FEBS J* 277: 1465–1480, 2010.
 232. Requena JR, Chao CC, Levine RL, and Stadtman ER. Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. *Proc Natl Acad Sci U S A* 98: 69–74, 2001.
 233. Rhee SG, Jeong W, Chang TS, and Woo HA. Sulfiredoxin, the cysteine sulfenic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. *Kidney Int Suppl* S3–S8, 2007.
 234. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, and Seraphin B. A generic protein purification method for protein complex characterization and proteome exploration. *Nat Biotechnol* 17: 1030–1032, 1999.
 235. Rodgers MA and Garrison WM. Excited-molecule reactions in the radiolysis of peptides in concentrated aqueous solution. *J Phys Chem* 72: 758–759, 1968.
 236. Roos G and Messens J. Protein sulfenic acid formation: from cellular damage to redox regulation. *Free Radic Biol Med* 51: 314–326, 2011.
 237. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, and Braunwald E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. *Circulation* 125: 233–240, 2012.
 238. Sagemark J, Elgan TH, Burglin TR, Johansson C, Holmgren A, and Berndt KD. Redox properties and evolution of human glutaredoxins. *Proteins* 68: 879–892, 2007.
 239. Sagher D, Brunell D, Hejtmancik JF, Kantorow M, Brot N, and Weissbach H. Thionein can serve as a reducing agent for the methionine sulfoxide reductases. *Proc Natl Acad Sci U S A* 103: 8656–8661, 2006.
 240. Salmon AB, Perez VI, Bokov A, Jernigan A, Kim G, Zhao H, Levine RL, and Richardson A. Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span. *FASEB J* 23: 3601–3608, 2009.
 241. Saurin AT, Neubert H, Brennan JP, and Eaton P. Widespread sulfenic acid formation in tissues in response to hydrogen peroxide. *Proc Natl Acad Sci U S A* 101: 17982–17987, 2004.
 242. Schey KL and Finley EL. Identification of peptide oxidation by tandem mass spectrometry. *Acc Chem Res* 33: 299–306, 2000.
 243. Schoneich C. Mechanisms of metal-catalyzed oxidation of histidine to 2-oxo-histidine in peptides and proteins. *J Pharm Biomed Anal* 21: 1093–1097, 2000.
 244. Schoneich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. *Biochim Biophys Acta* 1703: 111–119, 2005.
 245. Schulz-Menger J, Maisch B, Abdel-Aty H, and Pankuweit S. Integrated biomarkers in cardiomyopathies: cardiovascular magnetic resonance imaging combined with molecular and immunologic markers—a stepwise approach for diagnosis and treatment. *Herz* 32: 458–472, 2007.
 246. Schwarzer E, Muller O, Arese P, Siems WG, and Grune T. Increased levels of 4-hydroxynonenal in human monocytes fed with malarial pigment hemozoin. A possible clue for hemozoin toxicity. *FEBS Lett* 388: 119–122, 1996.
 247. Seo YH and Carroll KS. Quantification of protein sulfenic acid modifications using isotope-coded dimedone and iododimedone. *Angew Chem* 50: 1342–1345, 2011.
 248. Seth D and Stamler JS. The SNO-proteome: causation and classifications. *Curr Opin Chem Biol* 15: 129–136, 2011.
 249. Sethuraman M, McComb ME, Heibeck T, Costello CE, and Cohen RA. Isotope-coded affinity tag approach to identify and quantify oxidant-sensitive protein thiols. *Mol Cell Proteomics* 3: 273–278, 2004.
 250. Sethuraman M, McComb ME, Huang H, Huang S, Heibeck T, Costello CE, and Cohen RA. Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. *J Proteome Res* 3: 1228–1233, 2004.
 251. Sfakianos MK, Wilson L, Sakalian M, Falany CN, and Barnes S. Conserved residues in the putative catalytic triad of human bile acid Coenzyme A:amino acid N-acyltransferase. *J Biol Chem* 277: 47270–47275, 2002.
 252. Shao B, Pennathur S, and Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. *J Biol Chem* 287: 6375–6386, 2012.
 253. Shao CH, Capek HL, Patel KP, Wang M, Tang K, DeSouza C, Nagai R, Mayhan W, Periasamy M, and Bidasee KR. Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes. *Diabetes* 60: 947–959, 2011.
 254. Shao CH, Rozanski GJ, Nagai R, Stockdale FE, Patel KP, Wang M, Singh J, Mayhan WG, and Bidasee KR. Carbo-

- nylation of myosin heavy chains in rat heart during diabetes. *Biochem Pharmacol* 80: 205–217, 2010.
255. Sharov VS, Dremina ES, Galeva NA, Gerstenecker GS, Li X, Dobrowsky RT, Stobaugh JF, and Schoneich C. Fluorogenic tagging of peptide and protein 3-nitrotyrosine with 4-(aminomethyl)-benzenesulfonic acid for quantitative analysis of protein tyrosine nitration. *Chromatographia* 71: 37–53, 2010.
256. Silvester JA, Timmins GS, and Davies MJ. Photo-dynamically generated bovine serum albumin radicals: evidence for damage transfer and oxidation at cysteine and tryptophan residues. *Free Radic Biol Med* 24: 754–766, 1998.
257. Smallwood HS, Lourette NM, Boschek CB, Bigelow DJ, Smith RD, Paša-Tolić L, and Squier TC. Identification of a denitrase activity against calmodulin in activated macrophages using high-field liquid chromatography–FTICR mass spectrometry. *Biochemistry* 46: 10498–10505, 2007.
258. Sohail RS, Marzabadi MR, Galaris D, and Brunk UT. Effect of ambient oxygen concentration on lipofuscin accumulation in cultured rat heart myocytes—a novel in vitro model of lipofuscinogenesis. *Free Radic Biol Med* 6: 23–30, 1989.
259. Soreghan BA, Yang F, Thomas SN, Hsu J, and Yang AJ. High-throughput proteomic-based identification of oxidatively induced protein carbonylation in mouse brain. *Pharm Res* 20: 1713–1720, 2003.
260. Spies-Martin D, Sommerburg O, Langhans CD, and Leichsenring M. Measurement of 4-hydroxynonenal in small volume blood plasma samples: modification of a gas chromatographic-mass spectrometric method for clinical settings. *J Chromatogr B Anal Technol Biomed Life Sci* 774: 231–239, 2002.
261. Srivastava S, Chandra A, Wang LF, Seifert WE, Jr., DaGue BB, Ansari NH, Srivastava SK, and Bhatnagar A. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. *J Biol Chem* 273: 10893–10900, 1998.
262. St-Pierre J, Buckingham JA, Roebuck SJ, and Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. *J Biol Chem* 277: 44784–44790, 2002.
263. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. *Free Radic Biol Med* 9: 315–325, 1990.
264. Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. *Annu Rev Biochem* 62: 797–821, 1993.
265. Stadtman ER and Levine RL. Chemical modification of proteins by reactive oxygen species. In: *Redox Proteomics*, edited by Dalle-Donne I, Scaloni A, and Butterfield DA (Series Editors: Desiderio DM and Nibbering NM). Hoboken, NJ: John Wiley & Sons, Inc., 2006, pp. 1–23.
266. Stadtman ER, Moskovitz J, and Levine RL. Oxidation of methionine residues of proteins: biological consequences. *Antioxid Redox Signal* 5: 577–582, 2003.
267. Staniszevska M and Nagaraj RH. Detection of kynurenine modifications in proteins using a monoclonal antibody. *J Immunol Methods* 324: 63–73, 2007.
268. Steen H and Mann M. The ABC's (and XYZ's) of peptide sequencing. *Nat Rev Mol Cell Biol* 5: 699–711, 2004.
269. Stevens SM, Jr., Rauniyar N, and Prokai L. Rapid characterization of covalent modifications to rat brain mitochondrial proteins after ex vivo exposure to 4-hydroxy-2-nonenal by liquid chromatography-tandem mass spectrometry using data-dependent and neutral loss-driven MS3 acquisition. *J Mass Spectrom* 42: 1599–1605, 2007.
270. Sullivan DM, Levine RL, and Finkel T. Detection and affinity purification of oxidant-sensitive proteins using biotinylated glutathione ethyl ester. *Methods Enzymol* 353: 101–113, 2002.
271. Sultana R, Perluigi M, Newman SF, Pierce WM, Cini C, Coccia R, and Butterfield DA. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. *Antioxid Redox Signal* 12: 327–336, 2010.
272. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, and Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. *Neurobiol Dis* 22: 76–87, 2006.
273. Sun J, Steenbergen C, and Murphy E. S-nitrosylation: NO-related redox signaling to protect against oxidative stress. *Antioxid Redox Signal* 8: 1693–1705, 2006.
274. Suzuki YJ, Carini M, and Butterfield DA. Protein carbonylation. *Antioxid Redox Signal* 12: 323–325, 2010.
275. Swallow AJ. *Radiation Chemistry of Organic Compounds*. Oxford, New York: Pergamon Press, 1960, p. 380.
276. Takanishi CL, Ma LH, and Wood MJ. A genetically encoded probe for cysteine sulfenic acid protein modification in vivo. *Biochemistry* 46: 14725–14732, 2007.
277. Tarrago L, Laugier E, Zaffagnini M, Marchand CH, Le Marechal P, Lemaire SD, and Rey P. Plant thioredoxin CDSP32 regenerates 1-cys methionine sulfoxide reductase B activity through the direct reduction of sulfenic acid. *J Biol Chem* 285: 14964–14972, 2010.
278. Taylor SW, Fahy E, Murray J, Capaldi RA, and Ghosh SS. Oxidative post-translational modification of tryptophan residues in cardiac mitochondrial proteins. *J Biol Chem* 278: 19587–19590, 2003.
279. Thomson K. *Investigating and Detecting Biomarkers for Oxidative Stress*. Glasgow: University of Glasgow, 2011, p. 228.
280. Todorovski T, Fedorova M, and Hoffmann R. Mass spectrometric characterization of peptides containing different oxidized tryptophan residues. *J Mass Spectrom* 46: 1030–1038, 2011.
281. Tong X, Hou X, Jourde'heuil D, Weisbrod RM, and Cohen RA. Upregulation of Nox4 by TGF[β]1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. *Circ Res* 107: 975–983, 2010.
282. Traore DA, El Ghazouani A, Jacquamet L, Borel F, Ferrer JL, Lascoux D, Ravanat JL, Jaquinod M, Blondin G, Caux-Thang C, Duarte V, and Latour JM. Structural and functional characterization of 2-oxo-histidine in oxidized PerR protein. *Nat Chem Biol* 5: 53–59, 2009.
283. Truong TH, Garcia FJ, Seo YH, and Carroll KS. Isotope-coded chemical reporter and acid-cleavable affinity reagents for monitoring protein sulfenic acids. *Bioorg Med Chem Lett* 21: 5015–5020, 2011.
284. Tsai A, Kulmacz RJ, and Palmer G. Spectroscopic evidence for reaction of prostaglandin H synthase-1 tyrosyl radical with arachidonic acid. *J Biol Chem* 270: 10503–10508, 1995.
285. Tsai L, Szveda PA, Vinogradova O, and Szveda LI. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine. *Proc Natl Acad Sci U S A* 95: 7975–7980, 1998.
286. Turell L, Botti H, Carballal S, Ferrer-Sueta G, Souza JM, Duran R, Freeman BA, Radi R, and Alvarez B. Reactivity of sulfenic acid in human serum albumin. *Biochemistry* 47: 358–367, 2008.
287. Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, Keeley EC, Cigarroa JE, Lange RA, Hillis LD,

- and de Lemos JA. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. *J Am Coll Cardiol* 57: 2398–2405, 2011.
288. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, and Stadtman ER. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. *Arch Biochem Biophys* 324: 241–248, 1995.
 289. Uchida K, Szewda LI, Chae HZ, and Stadtman ER. Immunohistochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. *Proc Natl Acad Sci U S A* 90: 8742–8746, 1993.
 290. Vaishnav RA, Getchell ML, Poon HF, Barnett KR, Hunter SA, Pierce WM, Klein JB, Butterfield DA, and Getchell TV. Oxidative stress in the aging murine olfactory bulb: redox proteomics and cellular localization. *J Neurosci Res* 85: 373–385, 2007.
 291. van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios-Callender M, Erusalimsky JD, Quaschnig T, Malinski T, Gygi D, Ullrich V, and Luscher TF. Enhanced peroxynitrite formation is associated with vascular aging. *J Exp Med* 192: 1731–1744, 2000.
 292. Venardos KM, Perkins A, Headrick J, and Kaye DM. Myocardial ischemia-reperfusion injury, antioxidant enzyme systems, and selenium: a review. *Curr Med Chem* 14: 1539–1549, 2007.
 293. Vila A, Tallman KA, Jacobs AT, Liebler DC, Porter NA, and Marnett LJ. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. *Chem Res Toxicol* 21: 432–444, 2008.
 294. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. *Free Radic Biol Med* 18: 93–105, 1995.
 295. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF, Jr., Hunt NH, and Stocker R. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. *Nat Med* 16: 279–285, 2010.
 296. Weerapana E, Speers AE, and Cravatt BF. Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)—a general method for mapping sites of probe modification in proteomes. *Nat Protoc* 2: 1414–1425, 2007.
 297. Weerapana E, Wang C, Simon GM, Richter F, Khare S, Dillon MB, Bachovchin DA, Mowen K, Baker D, and Cravatt BF. Quantitative reactivity profiling predicts functional cysteines in proteomes. *Nature* 468: 790–795, 2010.
 298. Weinstein DM, Mihm MJ, and Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. *J Pharmacol Exp Ther* 294: 396–401, 2000.
 299. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, and Baynes JW. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. *J Clin Invest* 100: 839–846, 1997.
 300. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, and Bauersachs J. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. *Hypertension* 54: 338–344, 2009.
 301. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. *Nat Chem Biol* 4: 278–286, 2008.
 302. Wong CM, Marcocci L, Liu L, and Suzuki YJ. Cell signaling by protein carbonylation and decarbonylation. *Antioxid Redox Signal* 12: 393–404, 2010.
 303. Wu Y, Kwon KS, and Rhee SG. Probing cellular protein targets of H₂O₂ with fluorescein-conjugated iodoacetamide and antibodies to fluorescein. *FEBS Lett* 440: 111–115, 1998.
 304. Xu S, Ying J, Jiang B, Guo W, Adachi T, Sharov V, Lazar H, Menzoian J, Knyushko TV, Bigelow D, Schöneich C, and Cohen RA. Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. *Am J Physiol Heart Circ Physiol* 290: H2220–H2227, 2006.
 305. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, and Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. *J Clin Invest* 112: 1395–1406, 2003.
 306. Yang C-y, Gu Z-W, Yang M, Lin S-N, Siuzdak G, and Smith CV. Identification of modified tryptophan residues in apolipoprotein B-100 derived from copper ion-oxidized low-density lipoprotein. *Biochemistry* 38: 15903–15908, 1999.
 307. Yang Y, Ago T, Zhai P, Abdellatif M, and Sadoshima J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. *Circ Res* 108: 305–313, 2011.
 308. Ying J, Clavreul N, Sethuraman M, Adachi T, and Cohen RA. Thiol oxidation in signaling and response to stress: detection and quantification of physiological and pathological thiol modifications. *Free Radic Biol Med* 43: 1099–1108, 2007.
 309. Zhang H and Ge Y. Comprehensive analysis of protein modifications by top-down mass spectrometry. *Circ Cardiovasc Genet* 4: 711, 2011.
 310. Zhang Y, Sano M, Shinmura K, Tamaki K, Katsumata Y, Matsushashi T, Morizane S, Ito H, Hishiki T, Endo J, Zhou H, Yuasa S, Kaneda R, Suematsu M, and Fukuda K. 4-hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway. *J Mol Cell Cardiol* 49: 576–586, 2010.
 311. Zhao H, Sun J, Deschamps AM, Kim G, Liu C, Murphy E, and Levine RL. Myristoylated methionine sulfoxide reductase A protects the heart from ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* 301: H1513–H1518, 2011.
 312. Zhao R, Lind J, Merenyi G, and Eriksen TE. Kinetics of one-electron oxidation of thiols and hydrogen abstraction by thiyl radicals from α -amino C-H bonds. *J Am Chem Soc* 116: 12010–12015, 1994.
 313. Zhou X, Han P, Li J, Zhang X, Huang B, Ruan HQ, and Chen C. ESNOQ, proteomic quantification of endogenous S-nitrosation. *PLoS One* 5: e10015, 2010.
 314. Zima AV and Blatter LA. Redox regulation of cardiac calcium channels and transporters. *Cardiovasc Res* 71: 310–321, 2006.

Address correspondence to:
 Asst. Prof. Markus Michael Bachschmid
 Vascular Biology Section
 Boston University School of Medicine
 650 Albany St. X704
 Boston, MA 02118
 E-mail: bach@bu.edu

Date of first submission to ARS Central, May 16, 2012; date of acceptance, May 18, 2012.

Abbreviations Used

2DE = two-dimensional gel electrophoresis
 5-HT = serotonin or 5-hydroxytryptamine
 ADP = adenosine-5'-diphosphate
 ALDH2 = aldehyde dehydrogenase
 2/mitochondrial isoform
 Ang II = angiotensin II
 apoB-100 = apolipoprotein B
 AR = aldose reductase
 ARE = antioxidant- or electrophile-response
 element
 Arg = arginine
 ATP = adenosine-5'-triphosphate
 CaMKII = calmodulin kinase II
 CID = collision-induced dissociation
 CO = carbon monoxide
 CO₂ = carbon dioxide
 COFRADIC = combined fractional diagonal
 chromatography
 Cu = copper
 CVD = cardiovascular diseases
 Cys = cysteine
 cysTMT = cysteine specific tandem mass tags
 DCP = 3-(2,4-dioxycyclohexyl)propyl
 DNP = 2,4-dinitrophenol
 DOPA = dihydroxyphenylalanine
 DTNB = 5,5'-dithiobis-(2-nitrobenzoic acid)
 DUOX = dual oxidase (NADPH oxidase and
 peroxidase)
 ECD = electron capture dissociation
 ELISA = enzyme-linked immunosorbent assay
 eNOS = endothelial nitric oxide synthase
 OR NOSIII
 ESI = electrospray ionization
 Fe = iron
 GDP = guanosine diphosphate
 Glrx = glutaredoxin
 GSH = reduced glutathione
 GSNO = S-nitroso glutathione
 GSSG = oxidized glutathione
 GST = glutathione-S-transferase
 HDAC4 = histone deacetylase 4
 HIF1 α = hypoxia-inducible factor 1, α subunit
 His = histidine
 HNE = 4-hydroxynonenal
 H₂O₂ = hydrogen peroxide
 HOCl = hypochlorous acid
 HPLC = high performance (pressure) liquid
 chromatography
 HUVEC = human umbilical vein endothelial cells
 ICAT = isotope-coded affinity tags
 iNOS = inducible NO-synthase
 IsoTOP-ABPP = isotopic tandem orthogonal
 proteolysis-activity based protein
 profiling
 iTRAQ = isobaric tag for relative and absolute
 quantitation

Keap1 = Kelch-like ECH-associated protein 1
 KYN = kynurenine
 LC = liquid chromatography
 LTQ-FT = linear ion trap-Fourier transform ion
 cyclotron resonance mass
 spectrometer
 Lys = lysine
 MALDI = matrix-assisted laser desorption
 ionization
 MAP = mitogen activated protein
 MDA = malondialdehyde
 Met = methionine
 mir = micro RNA
 MS = mass spectrometry
 MS/MS = tandem mass spectrometry
 MsrA, MsrB = methionine sulfoxide reductase
 A or B isoform
 NADPH = nicotinamide adenine dinucleotide
 phosphate
 NFK = N-formylkynurenine
 *NO = nitric oxide
 NO₂ = nitrogen dioxide
 NOX = NADPH oxidase
¹O₂ = singlet oxygen
 *O₂⁻ = superoxide anions or superoxide
 *OH = hydroxyl radical
 OPTM = oxidative post-translational
 modification
 PDI = protein disulfide isomerase
 Phe = phenylalanine
 PKA = cAMP dependent protein kinase
 PN = peroxydinitrite or ONOO⁻
 RAC = resin-assisted capture
 RIGhT = reporter ion generation tag
 RNOS = reactive nitrogen and oxygen species
 R-SG and R₁-S-S-R₂ = disulfides
 R-SH = sulfhydryl group, thiol group
 R-SNO = S-Nitrosylation
 R-SOH = sulfenylation
 R-SO₂H = sulfinylation
 R-SO₃H = sulfonylation
 RyR₂ = ryanodine receptor
 SDS PAGE = sodium dodecyl sulfate
 polyacrylamide
 gel electrophoresis
 SERCA = sarcoplasmic/endoplasmic
 reticulum Ca²⁺ ATPase
 SILAC = stable-isotope labeling of amino
 acids in cell culture
 SOD = superoxide dismutase
 SUMO = small ubiquitin-like modifier
 T3, T4 = thyroxine-3 and 4
 TNB = 2-nitro-5-thiobenzoic acid
 TOF = time of flight
 Trp = tryptophan
 Trx = thioredoxin
 Tyr = tyrosine
 VEGF = vascular endothelial growth factor